AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON FEBRUARY 3, 1998.

REGISTRATION NO. 333-44919

================================================================================

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
------------------------

AMENDMENT NO. 1

FORM S-3
------------------------
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
------------------------

SOFAMOR DANEK GROUP, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

INDIANA 35-1580052
(STATE OR OTHER JURISDICTION OF (I.R.S. EMPLOYER
INCORPORATION OR ORGANIZATION) IDENTIFICATION NO.)
1800 PYRAMID PLACE
MEMPHIS, TENNESSEE 38132
(901) 396-2695

(ADDRESS, INCLUDING ZIP CODE, AND TELEPHONE NUMBER, INCLUDING AREA CODE, OF
REGISTRANT'S PRINCIPAL EXECUTIVE OFFICES)
------------------------
RICHARD E. DUERR, JR.
VICE PRESIDENT, GENERAL COUNSEL AND SECRETARY
SOFAMOR DANEK GROUP, INC.
1800 PYRAMID PLACE
MEMPHIS, TENNESSEE 38132
(901) 396-2695
(NAME, ADDRESS, INCLUDING ZIP CODE, AND TELEPHONE NUMBER, INCLUDING AREA CODE,
OF AGENT FOR SERVICE)
------------------------
COPY TO:

CREIGHTON O'M. CONDON, ESQ. GERALD S. TANENBAUM, ESQ.
STEPHEN T. GIOVE, ESQ. CAHILL GORDON & REINDEL
SHEARMAN & STERLING 80 PINE STREET
599 LEXINGTON AVENUE NEW YORK, NEW YORK 10005
NEW YORK, NEW YORK 10022 (212) 701-3000
(212) 848-4000

------------------------
APPROXIMATE DATE OF COMMENCEMENT OF PROPOSED SALE OF THE SECURITIES TO THE
PUBLIC:
From time to time after the effective date of this Registration Statement.

If the only securities being registered on this Form are being offered
pursuant to dividend or interest reinvestment plans, please check the following
box. [ ]
If any of the securities being registered on this Form are to be offered on
a delayed or continuous basis pursuant to Rule 415 under the Securities Act of
1933, other than securities offered only in connection with dividend or interest
reinvestment plans, check the following box. [ ]
If this Form is filed to register additional securities for an offering
pursuant to Rule 462(b) under the Securities Act, please check the following box
and list the Securities Act registration statement number of the earlier
effective registration statement for the same offering. [ ]
If this Form is a post-effective amendment filed pursuant to Rule 462(c)
under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement
for the same offering. [ ]
If delivery of the prospectus is expected to be made pursuant to Rule 434,
please check the following box. [ ]
------------------------

THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE OR
DATES AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT SHALL
FILE A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS REGISTRATION
STATEMENT SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTION 8(A) OF
THE SECURITIES ACT OF 1933 OR UNTIL THE REGISTRATION STATEMENT SHALL BECOME
EFFECTIVE ON SUCH DATE AS THE COMMISSION, ACTING PURSUANT TO SAID SECTION 8(A),
MAY DETERMINE.

================================================================================
2

INFORMATION CONTAINED HEREIN IS SUBJECT TO COMPLETION OR AMENDMENT. A
REGISTRATION STATEMENT RELATING TO THESE SECURITIES HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION. THESE SECURITIES MAY NOT BE SOLD NOR MAY
OFFERS TO BUY BE ACCEPTED PRIOR TO THE TIME THE REGISTRATION STATEMENT BECOMES
EFFECTIVE. THIS PROSPECTUS SHALL NOT CONSTITUTE AN OFFER TO SELL OR THE
SOLICITATION OF AN OFFER TO BUY NOR SHALL THERE BE ANY SALE OF THESE SECURITIES
IN ANY JURISDICTION IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL
PRIOR TO REGISTRATION OR QUALIFICATION UNDER THE SECURITIES LAWS OF ANY SUCH
JURISDICTION.

PROSPECTUS Subject to Completion

Dated February 3, 1998

2,800,000 Shares

[SOFAMOR DANEK GROUP LOGO]
Common Stock
(no par value)

Of the 2,800,000 shares of Common Stock (the "Common Stock") of Sofamor Danek
Group, Inc. (the "Company") offered hereby (the "Offering"), 1,200,000 shares
are being offered by the Company and 1,600,000 shares are being offered by the
selling shareholders named herein (the "Selling Shareholders"). See "Selling
Shareholders." The Company will not receive any of the proceeds from the sale of
the Common Stock by the Selling Shareholders.

The Common Stock is listed on the New York Stock Exchange ("NYSE") under the
symbol "SDG." On February 2, 1998, the reported closing sale price of the Common
Stock on the NYSE was $66.063 per share. See "Price Range of Common Stock and
Dividend Policy."

SEE "RISK FACTORS" COMMENCING ON PAGE 10 FOR CERTAIN INFORMATION THAT SHOULD BE
CONSIDERED BY PROSPECTIVE INVESTORS.

THESE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND
EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION NOR HAS THE SECURITIES
AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION PASSED UPON THE
ACCURACY OR ADEQUACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A
CRIMINAL OFFENSE.

- ----------------------------------------------------------------------------------------------------------
PRICE TO UNDERWRITING PROCEEDS TO
PUBLIC DISCOUNT(1) COMPANY(2) PROCEEDS TO
SELLING
SHAREHOLDERS(3)
- ----------------------------------------------------------------------------------------------------------

Per share $ $ $ $
- ----------------------------------------------------------------------------------------------------------
Total(4) $ $ $ $
- ----------------------------------------------------------------------------------------------------------

(1) The Company and the Selling Shareholders have agreed to indemnify the
Underwriters against certain liabilities, including liabilities under the
Securities Act of 1933, as amended. See "Underwriting."
(2) Before deducting expenses of the Offering payable by the Company estimated
at $ .
(3) Before deducting expenses of the Offering payable by the Selling
Shareholders estimated at $ .
(4) The Company has granted to the Underwriters an option, exercisable within 30
days after the date of this Prospectus, to purchase up to an additional 420,000
shares of Common Stock on the same terms as set forth above, solely to cover
over-allotments, if any. If such option is exercised in full, the total Price to
Public, Underwriting Discount and Proceeds to Company will be $ ,
$ and $ , respectively. See "Underwriting."

The shares of Common Stock being offered by this Prospectus are being offered by
the Underwriters, subject to prior sale, when, as and if delivered to and
accepted by the Underwriters, and subject to approval of certain legal matters
by Cahill Gordon & Reindel, counsel for the Underwriters. It is expected that
delivery of the shares of Common Stock offered hereby will be made against
payment therefor on or about , 1998 at the offices of J.P. Morgan
Securities Inc., 60 Wall Street, New York, New York.

J.P. MORGAN & CO.
PAINEWEBBER INCORPORATED
SALOMON SMITH BARNEY
, 1998
3

[Photographs of certain Sofamor Danek products under the heading "Spinal
Implants" and "Surgical Navigation Systems" and, under the headings "Research
and Product Development," products under the subheadings "Biological Products"
and "Interbody Fusion Devices."]

CERTAIN PERSONS PARTICIPATING IN THIS OFFERING MAY ENGAGE IN TRANSACTIONS THAT
STABILIZE, MAINTAIN OR OTHERWISE AFFECT THE PRICE OF THE COMMON STOCK.
SPECIFICALLY, THE UNDERWRITERS MAY OVERALLOT IN CONNECTION WITH THE OFFERING,
AND MAY BID FOR, AND PURCHASE, SHARES OF THE COMMON STOCK IN THE OPEN MARKET.
FOR A DESCRIPTION OF THESE ACTIVITIES, SEE "UNDERWRITING."

2
4

No person has been authorized to give any information or to make any
representation other than those contained in this Prospectus, and if given or
made, such information or representation must not be relied upon as having been
authorized by the Company or by any of the Underwriters. This Prospectus does
not constitute an offer to sell, or a solicitation of an offer to buy, any
securities in any jurisdiction to any person to whom it is unlawful to make such
offer or solicitation. Neither the delivery of this Prospectus nor any sale made
hereunder shall, under any circumstances, create any implication that there has
been no change in the affairs of the Company since the date hereof.

No action has been or will be taken in any jurisdiction by the Company or by any
Underwriter that would permit a public offering of the Common Stock or
possession or distribution of this Prospectus in any jurisdiction where action
for the purpose is required, other than in the United States. Persons into whose
possession this Prospectus comes are required by the Company and the
Underwriters to inform themselves about and to observe any restrictions as to
the offering of the Common Stock and the distribution of this Prospectus.

TABLE OF CONTENTS

PAGE

Available Information....................... 3
Incorporation of Certain Documents by
Reference................................. 4
Prospectus Summary.......................... 5
Risk Factors................................ 10
Use of Proceeds............................. 16
Price Range of Common Stock and Dividend
Policy.................................... 16
Capitalization.............................. 17
Selected Consolidated Financial Data........ 18

PAGE

Management's Discussion and Analysis of
Financial Condition and Results of
Operations................................ 19
Business.................................... 24
Management.................................. 35
Selling Shareholders........................ 38
Description of Capital Stock................ 39
Underwriting................................ 40
Legal Matters............................... 41
Experts..................................... 41

"Sofamor(TM)," "Danek(TM)," "CCD(TM)," "CD(TM)," "CD HORIZON(TM),"
"CROSSLINK(R)," "MEDNEXT(R)," "ORION(TM)," "STEALTHSTATION(TM)," "TIMESH(TM)"
and "TSRH(R)" are the trademarks of the Company. All other brand names or
trademarks appearing in this Prospectus are the property of their respective
owners.

AVAILABLE INFORMATION

The Company is subject to the informational requirements of the Securities
Exchange Act of 1934, as amended (the "Exchange Act"), and in accordance
therewith files reports, proxy statements and other information with the
Securities and Exchange Commission (the "Commission"). Such reports, proxy
statements and other information can be inspected and copied at the public
reference facilities maintained by the Commission at Judiciary Plaza, 450 Fifth
Street, N.W., Washington, DC 20549, and at the following Regional Offices of the
Commission: 500 West Madison Street, Suite 1400, Chicago, IL 60661 and 7 World
Trade Center, 13th Floor, New York, NY 10048. Copies of such material can also
be obtained from the Public Reference section of the Commission at Judiciary
Plaza, 450 Fifth Street, N.W., Washington, DC 20549, at prescribed rates. The
Common Stock is traded on the NYSE, and reports, proxy statements and other
information concerning the Company may be inspected at the offices of the NYSE,
20 Broad Street, New York, NY 10005. In addition, registration statements and
certain other filings made with the Commission through its Electronic Data
Gathering, Analysis and Retrieval ("EDGAR") system are publicly available
through the Commission's site on the Internet's World Wide Web, located at
http://www.sec.gov.

This Prospectus constitutes a part of the registration statement on Form S-3
(together with all amendments and exhibits thereto, the "Registration
Statement") filed by the Company with the Commission through EDGAR under the
Securities Act of 1933, as amended (the "Securities Act"), with respect to the
securities offered hereby. This Prospectus does not contain all of the
information set forth in the Registration Statement, certain parts of which are
omitted in accordance with the rules and regulations of the Commission.
Reference is made to such Registration Statement and the exhibits relating
thereto for further information with respect to the Company and the shares of
Common Stock offered hereby. The Underwriters of the shares of Common Stock
offered hereby are herein collectively referred to as the "Underwriters."

3
5

INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE

The following documents filed by the Company with the Commission are
incorporated herein by reference:

(1) The Company's Annual Report on Form 10-K for the year ended December 31,
1996;

(2) The Company's Quarterly Reports on Form 10-Q for the fiscal quarters ended
March 31, 1997, June 30, 1997 and September 30, 1997;

(3) The Company's Current Reports on Form 8-K dated January 7, 1997 and February
3, 1998; and

(4) The description of Common Stock contained in the Company's Registration
Statement on Form 8-A filed with the Commission effective April 17, 1991,
including any amendment or report filed for the purposes of updating such
description.

All documents filed by the Company with the Commission pursuant to Section
13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the date of this
Prospectus and prior to the termination of the Offering shall be deemed to be
incorporated herein by reference and to be a part hereof on and from the date of
filing of such documents. Any statement contained in a document incorporated or
deemed to be incorporated by reference in this Prospectus shall be deemed to be
modified or superseded for purposes of this Prospectus to the extent that a
statement contained herein or incorporated herein by reference or in any other
subsequently filed document that also is or is deemed to be incorporated by
reference herein modifies or supersedes such statement. Any statement so
modified or superseded shall not be deemed, except as so modified or superseded,
to constitute a part of this Prospectus.

The Company will provide without charge to each person, including any beneficial
owner, to whom this Prospectus is delivered, upon the written or oral request of
such person, a copy of any or all documents incorporated by reference in this
Prospectus (not including, however, the exhibits to such documents unless such
exhibits are specifically incorporated by reference in such information).
Requests for such documents should be directed to: Sofamor Danek Group, Inc.,
1800 Pyramid Place, Memphis, TN 38132, Attention: Secretary, telephone number
(901) 396-2695.

4
6

PROSPECTUS SUMMARY

The following summary is qualified in its entirety by the more detailed
information and financial statements and notes thereto appearing elsewhere and
incorporated by reference in this Prospectus. Unless the context requires
otherwise, the "Company" and "Sofamor Danek" refer to Sofamor Danek Group, Inc.,
an Indiana corporation, and its subsidiaries. Except for the historical
information contained in this Prospectus, the matters discussed herein
(including, in particular, those discussed in "Management's Discussion and
Analysis of Financial Condition and Results of Operations" and
"Business -- Legal Proceedings") are forward-looking in nature and involve risks
and uncertainties. The Company's actual results may differ significantly from
the results discussed in forward-looking statements. Factors that might cause or
contribute to such differences include, but are not limited to, those discussed
in "Risk Factors." Except as otherwise noted, all information contained in this
Prospectus assumes no exercise of the Underwriters' over-allotment option.

THE COMPANY

Sofamor Danek is primarily involved in developing, manufacturing and marketing
devices, instruments, computer-assisted visualization products and biomaterials
used in the treatment of spinal and cranial disorders. In 1997, the Company held
an approximately 50% market share of the worldwide spinal implant market, a
rapidly growing market which exceeded $500 million in worldwide sales. In
addition to its leadership position in the spinal implant market, the Company
provides a comprehensive line of products for the spinal surgeon and
neurosurgeon, including the STEALTHSTATION(TM) Image Guided Surgery System (the
"STEALTHSTATION(TM)"), the MicroEndoscopic Discectomy System (the "MED System")
for minimally invasive discectomies, MEDNEXT(R) high speed drills and TIMESH(TM)
cranial plates. As of December 31, 1997, the Company had a total of 150 U.S.
Food and Drug Administration ("FDA") 510(k) premarket clearances ("510(k)
Clearances") for spinal and neurosurgical products. The Company also has a broad
pipeline of spinal and neurosurgical products under development to augment its
existing product offerings and further advance the state of the art of surgical
and diagnostic procedures. Key products under development include the Novus line
of threaded interbody fusion devices, including the Novus LC, a titanium,
threaded, hollow, perforated cylinder that is packed with bone graft (the "Novus
Cage") and is currently being marketed for use in certain non-U.S. countries.
Other key products under development include biological products to induce bone
growth, prosthetic discs and products utilizing visualization technology to aid
surgeons. The Company has approximately 300 patents and patent applications in
the United States. For the year ended December 31, 1997, the Company generated
$312.9 million in revenues and $56.8 million in net income.

SPINAL IMPLANT INSTRUMENTATION AND THREADED CORTICAL BONE DOWELS

The objective of spinal implants is to increase spinal stability and facilitate
the bone growth required for fusion of the vertebrae of the spine. Fusion
immobilizes the vertebrae, which generally relieves the pressure on the nerves
of the spinal column and alleviates chronic back pain. Approximately 500,000
spinal fusion procedures were performed worldwide in 1997, and spinal implants
(commonly referred to as "instrumentation") are currently used in approximately
40% of these procedures. The Company believes that the success rate for fusion
with instrumentation is over 90%. Spinal implant procedure growth will be driven
by continued penetration of instrumentation, technological advances and
demographics. The Company's spinal systems include the TSRH(R) Spinal System,
the Cotrel-Dubousset ("CD(TM)") line of products and the ORION(TM) Anterior
Cervical Plate System (the "ORION(TM) System"). These lines of surgical implants
include tools for fusion such as rods, plates, screws, hooks, locking bolts and
transverse traction devices that lock implants together. The Company markets
products which treat degenerative diseases, deformities and trauma in all
regions of the spine. Spinal surgeons and neurosurgeons choose a spinal implant
system based on, among other things, the nature and location of the spinal
instability. The Company currently markets approximately 33 spinal implant
product lines.

In addition, the Company markets the Novus Cage in certain non-U.S. countries
and is currently seeking FDA approval to market the product in the United
States. The Novus Cage is implanted into the disc space between successive
vertebrae. Interbody fusion cages currently on the market can be implanted less
invasively than traditional implants and are intended to be used for certain
spinal fusions in the lumbar region of the spine as well as for supporting the
spine after discectomies. In the United States, approximately 400,000
discectomies are performed each year to remove spinal discs. These procedures
historically have not used a significant amount of surgical instrumentation. In
1997, worldwide interbody fusion cage sales for all companies were approximately
$115 million. In addition to the Novus Cage, the Company currently distributes
threaded Cortical Bone Dowels, a product made of human bone, in the United
States on behalf of the University of Florida Tissue Bank ("UFTB") pursuant to
an exclusive agreement. Spinal implant products and threaded Cortical Bone
Dowels accounted for $260.5 million, or 83%, of Sofamor Danek's revenues in
1997.

5
7

SURGICAL SYSTEMS

The STEALTHSTATION(TM) is an image-guided system which assists spinal surgeons
and neurosurgeons in precisely positioning surgical instruments in a patient.
Specifically, the STEALTHSTATION(TM) is a frameless stereotactic workstation
that takes data from CT scans or magnetic resonance images, converts this data
into three dimensional images and displays this data, together with the precise
location of the surgical instrument, on a real-time basis on a computer
workstation in the operating room. The Company believes that use of the
STEALTHSTATION(TM) enhances the accuracy of delicate surgical procedures and
allows surgeons to simulate a surgical plan before an operation, thereby
significantly reducing operating room time and the length of the patient's
hospital stay. The Company obtained 510(k) Clearance for the STEALTHSTATION(TM)
in January 1996 for use throughout the body when referencing a rigid anatomical
structure. In January 1998, the Company received 510(k) Clearance for intranasal
and sinus use. The Company believes that it has the leading share of the
worldwide, frameless stereotactic image-guided surgery market.

The Company's MED System, which consists of a large tube (or trocar), a
disposable endoscope, a light source and a video system, allows physicians to
perform minimally invasive discectomies by making an incision in the back of the
patient and removing all or part of a herniated disc in order to relieve
pressure on the spinal cord or nerve root. The ability to perform a discectomy
endoscopically using the MED System may eliminate the need for general
anesthesia. This procedure can be performed in an outpatient setting, as opposed
to requiring a hospital stay of approximately three days. The Company believes
the procedure also reduces patient recovery time, post-operative pain and
narcotic use.

RESEARCH AND PRODUCT DEVELOPMENT

In addition to its currently marketed products, Sofamor Danek has a broad
pipeline of spinal and neurosurgical products under development. In February
1995, the Company entered into a strategic alliance with Genetics Institute,
Inc. ("Genetics Institute") to develop biological products for use in spinal
applications. These products are being designed to use Genetics Institute's
recombinant human bone morphogenetic protein rhBMP-2 to induce bone growth for
the treatment of spinal disorders and replace the current therapy, which is
transplantation of bone tissue from the pelvis of the patient. The Company has
completed an FDA approved pilot study in which all 11 patients achieved fusion
in three months. Typically, fusion can take between 15 to 18 months to occur.
The Company is currently submitting an Investigational Device Exemption ("IDE")
to conduct a pivotal study with respect to rhBMP-2. The Company has obtained
exclusive North American rights to rhBMP-2 proprietary technologies and patents
for spinal applications. In addition, the Company is developing its Novus line
of interbody fusion devices, actively assessing various designs for products to
replace diseased and/or damaged discs and developing advanced visualization
technology to aid surgeons.

MARKETING AND DISTRIBUTION

Sofamor Danek markets its spinal implant and surgical systems products in the
United States directly to spinal surgeons and neurosurgeons who perform spinal
surgery. The Company distributes its products through its unique network of
approximately 200 commissioned sales representatives dedicated to Sofamor Danek
products. The Company markets its products internationally directly to spinal
surgeons and neurosurgeons in major markets, including the Benelux region,
France, Germany, Italy, Spain, the United Kingdom, South Africa, Canada, Puerto
Rico, Hong Kong, Japan, Korea, Australia and New Zealand, and indirectly in
approximately 60 other countries through a network of independent distributors
and agents. The Company believes that its distribution capabilities provide it
with significant competitive advantages by facilitating strong relationships
with the physicians, hospitals and clinics that comprise the Company's customer
base. The Company strengthens these relationships by organizing and sponsoring
the education of surgeons through medical symposia, seminars, payor relations
and practice management consulting. In order to meet the needs of hospitals and
clinics, the Company offers instrument and implant purchase alternatives. Its
premier distribution capability also enables it to attract alliance partners who
seek its distribution breadth.

* * *

The Company is an Indiana corporation formed in 1983. The Company changed its
name from Biotechnology, Inc. to Danek Group, Inc. in August 1990, and from
Danek Group, Inc. to Sofamor Danek Group, Inc. in June 1993. The Company's
executive offices, administrative offices and U.S. distribution facility are
located at 1800 Pyramid Place, Memphis, Tennessee 38132, and its telephone
number is (901) 396-2695. The Company's U.S. manufacturing operations are
conducted near Warsaw, Indiana, Broomfield, Colorado and West Palm Beach,
Florida. The Company also has a major manufacturing and distribution facility in
Rang-du-Fliers, France.

6
8

RECENT DEVELOPMENTS

In December 1997, the Company acquired certain net assets of MAN CERAMICS GMBH
("MAN Ceramics"), a subsidiary of the MAN Group of Munich. MAN Ceramics designs,
manufactures and markets carbon fiber interbody fusion devices in Europe. The
single filament carbon fiber is transparent in most types of imaging and has an
elasticity that is closer to bone than to other currently used implant
materials. Clinical studies in Europe included the testing of more than 1,400
devices over the past five years. FDA approval will be required in order to
market the product in the United States.

In January 1998, the Company entered into an exclusive, renewable five-year
strategic alliance with Vista Medical Technologies, Inc. ("Vista") to develop
and distribute advanced visualization systems based on Vista's proprietary head
mounted display and 3-D image acquisition technology for head, neck and spine
procedures. Pursuant to this alliance, the Company will distribute the
Stereo-Site visualization and information products of Vista's Head, Neck and
Spine Microsurgery Division.

On January 26, 1998, the Company entered into a stock exchange agreement with
the Selling Shareholders pursuant to which the Company repurchased beneficial
ownership of 3,337,272 shares of Common Stock held by Sofyc, S.A., a personal
holding company of the Selling Shareholders ("Sofyc"), in exchange for an
aggregate of 2,806,080 shares of Common Stock, $1.0 million in cash (less
certain expenses relating to the repurchase) and the Company's agreement to
repay certain outstanding loans of Sofyc equal to approximately $925,000 (the
"Sofyc Exchange"). The Company expects to incur a foreign tax liability of
approximately $10.5 million in connection with the Sofyc Exchange. For a more
detailed description of the transaction, see "Selling Shareholders."

The Company is currently seeking premarket approval ("PMA") for its Novus Cage
from the FDA. The Company submitted a PMA application to the FDA with data from
its prospective randomized study in March 1997. In December 1997, the FDA
informed the Company that additional data points will be required before the
Company's PMA application will be reconsidered. The Company is currently
compiling additional follow-up data on patients who participated in the clinical
trial.

RISK FACTORS

An investment in the shares of Common Stock offered hereby is speculative and
involves a high degree of risk. The risks include uncertainties relating to the
receipt of regulatory clearances for the use of products the Company is
currently developing or investigating; the success of the clinical
investigations the Company is currently conducting or intends to conduct in the
future; rapid technological change and obsolescence in the medical device
industry; the market acceptance of the Company's new products; potential
liability in ongoing orthopedic bone screw litigation and other product
liability claims against the Company; the availability of adequate insurance;
increasing competition in the medical device industry; patent and proprietary
technology upon which the Company depends; government regulation; risks
associated with international sales; the Company's dependence on the continued
service of key personnel; the Company's broad discretion in the use of the
proceeds from the Offering; the Company's dependence on its suppliers;
volatility in the price of the Company's stock; the potential adverse impact of
the Company's shares eligible for future sale; and the effect of certain charter
and bylaw provisions of the Company on stockholder action and changes in control
of the Company. See "Risk Factors."

7
9

THE OFFERING

COMMON STOCK OFFERED BY THE COMPANY.......... 1,200,000 shares
COMMON STOCK OFFERED BY THE SELLING
SHAREHOLDERS............................... 1,600,000 shares
COMMON STOCK OUTSTANDING AFTER THE
OFFERING................................... 25,850,649 shares(1)
USE OF PROCEEDS.............................. Approximately $42.7 million to repay outstanding
borrowings under the Company's U.S. revolving line of
credit (approximately $60.7 million in borrowings was
outstanding under such line as of February 2, 1998) and
the balance for general corporate purposes. See "Use of
Proceeds."
NYSE TRADING SYMBOL.......................... "SDG"

- ---------------

(1) Based on shares outstanding as of December 31, 1997. Reflects the Sofyc
Exchange and excludes: (i) 5,304,761 shares of Common Stock issuable upon
exercise of outstanding stock options at a weighted average exercise price of
$28.38 per share (of which options to purchase 1,380,345 shares were currently
exercisable) and (ii) 1,786,307 shares of Common Stock reserved for options that
may be granted in the future under the Company's stock plans.

8
10

SUMMARY CONSOLIDATED FINANCIAL DATA

-------------------------------------------------------
YEAR ENDED DECEMBER 31,
--------------------------------------------------------
-------------------------------------------------------
In thousands, except per share data 1997 1996 1995 1994 1993
-------- -------- -------- -------- --------

STATEMENTS OF INCOME DATA:
Revenues....................................................... $312,902 $244,525 $188,799 $161,677 $161,794
Cost of goods sold............................................. 58,068 45,005 40,309 35,295 35,893
-------- -------- -------- -------- --------
Gross profit................................................... 254,834 199,520 148,490 126,382 125,901
Operating expenses:
Selling, general and administrative.......................... 145,414 116,729 89,847 74,183 67,844
Research and development..................................... 19,747 15,926 13,980 11,572 11,488
License agreement acquisition charge......................... -- -- 45,337 -- --
Product liability litigation charge.......................... -- 50,000 -- -- --
Royalty expenses discontinued subsequent to the
combination................................................ -- -- -- -- 1,182
Distributor contract termination charge and related
amortization of
short-term intangibles..................................... -- -- -- 10,000 --
-------- -------- -------- -------- --------
Total operating expenses....................................... 165,161 182,655 149,164 95,755 80,514
-------- -------- -------- -------- --------
Income (loss) from operations.................................. 89,673 16,865 (674) 30,627 45,387
Other income (expense)......................................... 5 913 2,533 2,153 (179)
Interest expense............................................... (5,539) (3,744) (2,794) (629) (193)
Combination expense............................................ -- -- -- -- (9,958)
Non-recurring litigation award................................. -- -- -- (2,225) --
-------- -------- -------- -------- --------
Income (loss) from continuing operations before provision
(benefit) for and charge in lieu of income taxes and minority
interest..................................................... 84,139 14,034 (935) 29,926 35,057
Provision (benefit) for and charge in lieu of income taxes..... 25,073 1,293 (6,319) 6,052 14,429
-------- -------- -------- -------- --------
Income before loss from operations of discontinued segment and
minority interest............................................ 59,066 12,741 5,384 23,874 20,628
Loss from operations of discontinued segment................... -- -- -- -- (153)
Minority interest.............................................. (2,282) (1,474) (417) (97) (50)
-------- -------- -------- -------- --------
Net income..................................................... $ 56,784 $ 11,267 $ 4,967 $ 23,777 $ 20,425
======== ======== ======== ======== ========
Net income per share -- diluted................................ $ 2.12 $ 0.44 $ 0.20 $ 0.97 $ 0.83
Net income per share -- basic.................................. 2.29 0.46 0.21 0.99 0.85
======== ======== ======== ======== ========
Weighted average number of shares -- diluted................... 26,783 26,046 25,216 24,496 24,499
Weighted average number of shares -- basic..................... 24,797 24,284 23,846 24,014 24,133
======== ======== ======== ======== ========

------------------------
AT DECEMBER 31, 1997
-------------------------
In thousands ACTUAL AS ADJUSTED(1)
-------- --------------
(UNAUDITED)

CONSOLIDATED BALANCE SHEET DATA:
Working capital................................................................... $122,992 $159,121
Total assets...................................................................... 385,657 421,786
Short-term debt................................................................... 19,317 19,317
Long-term debt.................................................................... 60,650 23,100
Stockholders' equity.............................................................. 211,298 284,977

- ---------------

(1) As adjusted to give effect to the Sofyc Exchange, as described in "Selling
Shareholders," and the sale of 1,200,000 shares of Common Stock by the Company
in the Offering (assuming a price to public of $66.063 per share) and the
application of the net proceeds to the Company from the Offering as described in
"Use of Proceeds."

9
11

RISK FACTORS

An investment in the shares of Common Stock offered hereby involves a high
degree of risk. The following factors, in addition to the other information in
this Prospectus, should be considered carefully in evaluating the Company and
its business before purchasing shares of Common Stock offered hereby. This
Prospectus contains forward-looking statements which involve risks and
uncertainties. The Company's actual results may differ significantly from the
results discussed in forward-looking statements. Factors that might cause or
contribute to such a difference include, but are not limited to, those discussed
in the following risk factors.

UNCERTAINTY OF REGULATORY CLEARANCES; REGULATORY COMPLIANCE

The current and future preclinical and clinical testing, manufacturing,
labeling, distribution and promotion of the Company's products are subject to
extensive and rigorous government regulation by the FDA in the United States and
by comparable regulatory bodies in other countries. Noncompliance with
applicable regulatory requirements can lead to enforcement action by the FDA or
comparable foreign regulatory bodies that may result in, among other things,
warning letters, fines, injunctions, civil penalties, recall or seizure of
products, total or partial suspension of production, refusal by the government
to grant pre-market clearance or pre-market approval for devices, withdrawal of
marketing approvals and criminal prosecution.

Medical products regulated by the FDA are generally classified as devices and/or
drugs and/or biologics. Product development and clearance or approval within the
FDA framework may take a number of years and involve the expenditure of
substantial resources. There can be no assurance that the FDA will grant
clearance or approval for the Company's new products on a timely basis, if at
all, or that FDA review will not involve delays that will adversely affect the
Company's ability to commercialize additional products or expand permitted uses
of existing products. Delays in market introduction resulting from the FDA
review process could materially affect the Company's business, financial
condition and results of operations. Additionally, there can be no assurance
that the regulatory framework will not change or that additional regulation will
not arise at any stage of the Company's product development process which may
adversely affect approval of or delay an application or require additional
expenditures by the Company.

The Company's currently marketed products are classified as medical devices and
have received 510(k) Clearance. Generally, before a new medical device can be
introduced into the market in the United States, the manufacturer or distributor
must obtain either a 510(k) Clearance or FDA approval of a PMA application. If a
medical device manufacturer or distributor can establish that a device is
"substantially equivalent," in terms of safety and effectiveness, to a legally
marketed Class I or Class II device, or to a Class III device for which the FDA
has not called for PMA applications, the manufacturer or distributor may seek
clearance from the FDA to market the device by filing a 510(k) notification. A
510(k) notification may need to be supported by appropriate data establishing
the claim of substantial equivalence to the FDA. The FDA recently has been
requiring a more rigorous demonstration of substantial equivalence.

Even after regulatory clearance or approval to market a device is obtained from
the FDA, the Company may be required to make further filings with the FDA under
certain circumstances. FDA regulations require agency approval of a PMA
supplement or a new 510(k) Clearance for certain changes to a marketed device.
Failure of the Company to receive approval of a PMA supplement or new 510(k)
Clearance for a new intended use or for certain changes potentially affecting
the safety or effectiveness of an approved or cleared device on a timely basis,
or at all, may have a material adverse effect on the Company's business,
financial condition and results of operations. The FDA could also limit or
prevent the manufacture or distribution of the Company's products and has the
power to require the recall of such products. The FDA can also require a company
to stop marketing its products due to failure to comply with regulatory
standards or the occurrence of unforeseen problems following initial clearance
or approval. Significant delay or cost in obtaining, or failure to obtain, FDA
clearance or approval to market products, any FDA limitations on the use of the
Company's products or any withdrawal of clearance or approval by the FDA could
have a material adverse effect on the business, financial condition and results
of operations of the Company.

The Company is currently seeking FDA approval of a PMA application for its Novus
Cage, a spinal intervertebral fusion device. A PMA application must be supported
by extensive data. The PMA application process can be expensive, uncertain and
lengthy. A number of devices for which pre-market approval has been sought have
never been approved for marketing. The Company submitted a PMA application to
the FDA for the Novus Cage in March 1997, which included data from a prospective
randomized study. In December 1997, the FDA convened an advisory panel to review
and evaluate the application and provide recommendations to the agency as to
whether the device should be approved. The panel recommended that the
application not be approved at that time due generally to its lack of two-year
follow-up data. The Company is currently compiling additional follow-up data on
patients who participated in the clinical trial. There can be no assurance that,
upon

10
12

reviewing any additional data that the Company may submit, the FDA will approve
the Company's PMA application for the Novus Cage. Even if granted, the approval
may include significant limitations on the indicated uses for which a product
may be labeled and marketed.

Any products manufactured or distributed by the Company are subject to pervasive
and continuing regulation by the FDA and certain state agencies. The Company is
subject to routine inspections by FDA and state agencies and must comply with
the host of regulatory requirements that usually apply to medical devices in the
United States, including labeling regulations, the FDA's Quality System
Regulations ("QSR"), which include elaborate testing, control, documentation and
other quality assurance procedures, the FDA's Medical Device Reporting
Regulations, which require reporting to the FDA certain adverse events involving
devices, and the FDA's prohibitions against promoting products for unapproved or
"off-label" uses. The Company's failure to comply with applicable regulatory
requirements could result in enforcement action by the FDA, which could have a
material adverse effect on the Company's business, financial condition, and
results of operations.

Several of the Company's products under development will require clinical trials
to determine their safety and efficacy in humans for various conditions. There
can be no assurance that the Company will not encounter problems that will cause
it to delay or suspend clinical trials of any of these products. In addition,
there can be no assurance that such clinical trials, if completed, will
ultimately result in the approval of these products.

Unanticipated changes in existing regulatory requirements, failure of the
Company to comply with such requirements or adoption of new requirements could
have a material adverse effect on the Company's business, financial condition
and results of operations. The Company also is subject to numerous federal,
state and local laws relating to such matters as safe working conditions,
manufacturing practices, environmental protection, fire hazard control and
hazardous substance disposal. There can be no assurance the Company will not be
required to incur significant costs to comply with such laws and regulations in
the future or that such laws and regulations will not have a material adverse
effect on the Company's business, financial condition and results of operations.

In addition, FDA regulations depend heavily on administrative interpretation,
and there can be no assurance that future interpretations made by the FDA or
other regulatory bodies, with possible retroactive effect, will not adversely
affect the Company. In addition, changes in the existing regulations or policies
or adoption of new governmental regulations or policies could prevent or delay
regulatory approval of the Company's products.

RAPID TECHNOLOGICAL CHANGE; TECHNOLOGICAL OBSOLESCENCE; ACCEPTANCE OF NEW
PRODUCTS

The medical device industry is characterized by rapidly changing technology and
frequent new product introductions. The Company's future success will depend
largely on the Company's ability to develop and introduce in a timely manner new
products and enhancements that meet changing customer requirements and emerging
industry standards. Although the Company's strategy for growth includes the
introduction of new products, the development of new technologically advanced
products and enhancements is a complex and uncertain process requiring high
levels of innovation as well as the anticipation of technology and market
trends. The Company may not be able to respond effectively to technological
changes, emerging industry standards or product announcements by competitors, it
may not be able to identify, develop, manufacture, market, sell or support new
products and enhancements successfully and its new products or enhancements may
not achieve market acceptance. Market acceptance for products under development
could be adversely affected by numerous factors, including the lack of
availability of third-party reimbursement to consumers of such products, the
cost of the products, clinical acceptance thereof and effective physician
training. Market acceptance will also depend on the Company's ability to
demonstrate that such products are an attractive alternative to existing
products, which will depend on physicians' evaluations of the clinical safety
and efficacy, ease of use, reliability and cost-effectiveness of the products.
Furthermore, the Company believes that, once the products receive approval,
recommendations and endorsements by influential surgeons will be essential to
market acceptance of its products. There can be no assurance that the Company's
products under development will adequately demonstrate these characteristics or
that they will receive market acceptance among consumers or physicians. Any of
these events could have a material adverse effect on the Company's business,
financial condition and results of operations. See "Business--Research and
Product Development."

RISK OF ORTHOPEDIC BONE SCREW LITIGATION

11
13

labeling of medical devices), that pedicle fixation has not been proven safe and
effective in the context of FDA labeling standards, that some or all of the
spinal systems are defectively designed and manufactured and that plaintiffs
have suffered a variety of injuries as a result of their physicians' use of such
systems in pedicle fixation. The Company has also been named as a defendant in a
number of lawsuits instituted by plaintiffs who have received spinal implants
manufactured by other manufacturers and in which the Company is alleged to have
participated in a conspiracy among doctors, manufacturers, hospitals, teaching
institutions, professional societies and others to promote, in violation of
applicable law, the use of spinal implants.

As of December 31, 1997, approximately 2,800 plaintiffs were joined in lawsuits
against the Company. The Company is also named as a defendant in lawsuits
involving about 2,600 claimants where the Company is alleged to have conspired
with competitors and others illegally to promote the use of spinal implant
systems. Plaintiffs typically seek relief in the form of monetary damages, often
in unspecified amounts. Many of the plaintiffs only allege as monetary damages
an amount in excess of the jurisdictional minimum for the court in which the
case has been filed. A few suits also name as defendants various officers and
directors of the Company. Although certain of the plaintiffs' claims in a number
of the lawsuits against the Company have been dismissed, many of the plaintiffs'
claims against the Company are still pending. For a procedural history of the
litigation, see "Business--Legal Proceedings."

On January 6, 1997, the Company announced that its 1996 financial results would
include a pre-tax charge of $50.0 million relating to costs associated with the
litigation described above. The charge, which has been reflected in the
Company's 1996 financial statements, covers the reasonably foreseeable costs
that the Company was positioned in late December 1996 to estimate because the
litigation had progressed and because changes in the fourth quarter of 1996 had
occurred in facts and circumstances relating to the litigation. While it is not
possible to accurately predict the outcome of litigation, the amount of the
accrual which remained on the Company's consolidated balance sheet at December
31, 1997 represents the Company's best judgment of the probable reasonable costs
(in excess of amounts of insurance the Company believes are recoverable) to
defend and conclude the lawsuits based on the facts and circumstances currently
existing. The costs provided for in the accrual include, but are not limited to,
legal fees paid or anticipated to be paid and other costs related to the
Company's defense and conclusion of these matters. See "Business--Legal
Proceedings."

The actual costs to the Company could differ from the estimated charge and will
be dependent upon a number of factors that will not be known for some time,
including, among other things, the resolution of defense motions and the extent
of further discovery. Although an adverse resolution of the lawsuits could have
a material effect on the Company's results of operations and cash flows in
future periods, the Company does not believe that these matters will in the
future have a material adverse effect on its consolidated financial position.
The Company is unable to predict the ultimate outcome or the financial impact of
the product liability litigation.

RISK OF PRODUCT LIABILITY; ADEQUATE INSURANCE COVERAGE

The Company's business involves the risk of product liability claims which could
have a material adverse effect on the Company. The Company maintains product
liability insurance at coverage levels which it deems commercially reasonable.
Historically, the Company has been required to call on its insurance for product
liability claims and, assuming all amounts are paid by the insurance carriers,
the Company will exhaust its insurance coverage for the coverage year ended
November 1995. There can be no assurance that product liability or other claims
will not exceed such insurance coverage limits or that such insurance will
continue to be available on commercially acceptable terms, or at all. The
Company intends periodically to evaluate, depending on changing circumstances,
whether or not to obtain any additional product liability insurance coverage.
Even if the Company obtains additional product liability insurance, there can be
no assurance that it would prove adequate or that a product liability claim,
insured or uninsured, would not have a material adverse effect on the Company's
business, financial condition and results of operations. Even if a product
liability claim is not successful, the time and expense of defending against
such a claim may adversely affect the Company's business, financial condition
and results of operations. See "--Risk of Orthopedic Bone Screw Litigation" and
"Business--Legal Proceedings."

INCREASING COMPETITION

The medical device industry is subject to intense competition. The market for
products designed to treat spinal conditions is highly competitive, and the
Company expects competition to increase as a result of new entrants and
consolidations. Accordingly, the Company's future success will depend in part on
its ability to respond quickly to medical and technological change and user
preferences through the development and introduction of new products that are of
high quality and that address patient and surgeon requirements and, in part, on
its ability to differentiate its mature products from those of its competitors.
Worldwide, there are many firms producing spinal implant devices, and certain of
the Company's competitors

12
14

currently manufacture and sell interbody fusion cages that have received a PMA
from the FDA. A number of these firms have greater financial, research and
development, manufacturing and sales and marketing resources than the Company.
The Company's inability to compete effectively against existing or future
competitors would have a material adverse effect on its business, financial
condition and results of operations. See "Business--Competition."

DEPENDENCE ON PATENTS AND PROPRIETARY TECHNOLOGY

The patent and trade secret positions of medical device companies, including
those of the Company, are uncertain and involve complex and evolving legal and
factual questions. The coverage sought in a patent application either can be
denied or significantly reduced before or after the patent is issued.
Consequently, there can be no assurance that any patents from pending
applications or from any future patent application will be issued, that the
scope of the patent protection will exclude competitors or provide competitive
advantages to the Company, that any of the Company's patents will be held valid
if subsequently challenged or that others will not claim rights in or ownership
of the patents and other proprietary rights held by the Company. Since patent
applications are secret until patents are issued in the United States, or
corresponding applications are published in other countries, and since
publication of discoveries in the scientific or patent literature lags behind
actual discoveries, the Company cannot be certain that it was the first to file
patent applications for such inventions. In addition, there can be no assurance
that competitors, many of which have substantial resources, will not seek to
apply for and obtain patents that will prevent, limit or interfere with the
Company's ability to make, use or sell its products either in the United States
or in international markets. Further, the laws of certain foreign countries do
not protect the Company's intellectual property rights to the same extent as do
the laws of the United States. Litigation or regulatory proceedings. which could
result in substantial cost and uncertainty to the Company, may also be necessary
to enforce patent or other intellectual property rights of the Company or to
determine the scope and validity of other parties' proprietary rights. There can
be no assurance that the Company will have the financial resources to defend its
patents from infringement or claims of invalidity.

The Company also relies upon unpatented proprietary technology, and no assurance
can be given that others will not independently develop substantially equivalent
proprietary information and techniques or otherwise gain access to or disclose
the Company's proprietary technology or that the Company can meaningfully
protect its rights in such unpatented proprietary technology. The Company's
policy is to require each of its key employees, consultants, investigators and
advisors to execute a confidentiality agreement upon the commencement of an
employment or consulting relationship with the Company. These agreements
generally provide that all inventions conceived by the individual during the
term of the relationship shall be the exclusive property of the Company and
shall be kept confidential and not be disclosed to third parties except in
specified circumstances. There can be no assurance, however, that these
agreements will provide meaningful protection for the Company's proprietary
information in the event of unauthorized use or disclosure of such information.

Recently, Public Law 104-208 was signed into law in the United States and limits
the enforcement of patents relating to the performance of surgical or medical
procedures on a body. This law precludes medical practitioners and health care
entities, who practice these procedures, from being sued for patent
infringement. Therefore, depending upon how these limitations are interpreted by
the courts, they could have a material adverse effect on the Company's ability
to enforce any of its proprietary methods or procedures deemed to be surgical or
medical procedures on a body.

In addition, patent applications in the United States and foreign jurisdictions
are maintained in secrecy for a period after filing. Publication of discoveries
in the scientific or patent literature lags behind actual discoveries and the
filing of related patent applications. Although the Company has conducted
searches of certain patents issued to other companies, research and academic
institutions and others, patents issued and patent applications filed in the
United States or internationally relating to medical devices are numerous and
there can be no assurance that current and potential competitors and other third
parties have not filed, or in the future will not file applications for, or have
not received or in the future will not receive, patents or obtain additional
proprietary rights relating to products or processes used or proposed to be used
by the Company. In the event any pending applications provide proprietary rights
to third parties relating to products or processes used or proposed to be used
by the Company, the Company may be required to obtain licenses to patents or
proprietary rights of others.

The medical device industry in general has been characterized by substantial
litigation. Litigation regarding patent and other intellectual property rights,
whether with or without merit, could be time-consuming and expensive and could
divert the Company's technical and management personnel. The Company is involved
in litigation to defend against claims of infringement by the Company, to
enforce patents issued to the Company or to protect trade secrets of the
Company. If any relevant claims of third-party patents are held as infringed and
not invalid in any litigation or administrative proceeding, the Company could be
prevented from practicing the subject matter claimed in such patents or would be
required to obtain licenses from the patent owners of each such patent or to
redesign its products or processes to avoid infringement. In addition, in the
event of any possible infringement, there can be no assurance that the Company
would be successful in any attempt to

13
15

redesign its products or processes to avoid such infringement or in obtaining
licenses on terms acceptable to the Company, if at all. Accordingly, an adverse
determination in a judicial or administrative proceeding or failure by the
Company to redesign its products or processes or to obtain necessary licenses
could prevent the Company from manufacturing and selling its products, which
would have a material adverse effect on the Company's business, financial
condition and results of operations.

UNCERTAINTIES REGARDING GOVERNMENT REGULATION

Certain aspects of the Company's business are subject to federal and state
regulation. Federal regulation covers, among others, healthcare reimbursement
and the manufacturing, distribution and sale of the Company's medical devices.
The Company believes that its operations comply with applicable federal and
state laws and regulations in all material respects. However, changes in the law
or new interpretations of existing laws could have a material adverse effect on
permissible activities of the Company, the relative costs associated with doing
business and the amount of reimbursement for the Company's products and services
paid by government and other third-party payors. The unavailability of formal
advance rulings in most regulated areas subjects the Company to possible
subsequent adverse interpretations and rulings in this regard.

Political, economic and regulatory influences are subjecting the healthcare
industry in the United States to fundamental change. Although Congress has
failed to pass comprehensive healthcare reform legislation, the Company
anticipates that Congress and state legislatures will continue to review and
assess alternative healthcare delivery and payment systems and may in the future
propose and adopt legislation effecting fundamental changes in the healthcare
delivery system. The Company cannot predict the ultimate timing, scope or effect
of any legislation concerning healthcare reform. Any proposed federal
legislation, if adopted, could result in significant changes in the
availability, delivery, pricing and payment for healthcare services and
products. Various state agencies also have undertaken or are considering
significant healthcare reform initiatives. It is not possible to predict whether
any healthcare reform legislation will be adopted or, if adopted, the exact
manner and the extent to which the Company will be affected. Sales of a large
portion of the Company's products depend to a significant extent on the
availability of reimbursement to the Company's customers by government and
private insurance plans. Any healthcare reform legislation, if and when adopted,
could have a material adverse effect on the Company's business, financial
condition and results of operations.

RISKS ASSOCIATED WITH INTERNATIONAL SALES

A significant portion of the Company's revenues relate to international sales of
its products, which are subject to numerous risks. Regulatory requirements, as
well as pricing, marketing and distribution structures, vary significantly from
country to country. Additionally, international sales can be adversely affected
by limitations or disruptions caused by the imposition of government controls,
export licenses, political instability, trade restrictions, changes in foreign
tax laws or tariffs, or other trade regulations and difficulties coordinating
communications among and managing international operations. Moreover, the
Company's business, financial condition and results of operations may be
adversely effected by fluctuations in overseas economic conditions and
international currency exchange rates, as well as by increases in duty rates,
difficulty in obtaining export licenses, constraints on its ability to maintain
or increase prices and competition. There can be no assurance that the Company
will be able to successfully commercialize its existing products or any of its
future products in any international market, which could have a material adverse
effect on the Company's business, financial condition and results of operations.
See "--Uncertainty of Regulatory Clearances."

DEPENDENCE ON KEY PERSONNEL

The Company's future success depends in significant part upon the continued
service of certain key scientific, technical and managerial personnel and its
continuing ability to attract and retain highly qualified scientific, technical
and managerial personnel. Competition for such personnel is intense, and there
can be no assurance that the Company can retain its current personnel or that it
can attract, assimilate or retain other highly qualified scientific, technical
and managerial personnel in the future. The Company has taken steps to retain
its key employees, including the granting of stock options that vest over time.
The loss of key personnel, especially if without advanced notice, or the
inability to hire or retain qualified personnel could have a material adverse
effect upon the Company's business, financial condition and results of
operations.

BROAD DISCRETION AS TO USE OF PROCEEDS

Of the net proceeds to the Company from the Offering, approximately $32.9
million (approximately $59.5 million if the Underwriters' over-allotment option
is exercised in full) has not currently been allocated for a specific use by the
Company. The Company's management therefore will retain broad discretion in the
allocation of a significant portion of the net proceeds. See "Use of Proceeds."

14
16

DEPENDENCE ON SUPPLIERS

The Cortical Bone Dowel, a product the Company distributes on behalf of the
UFTB, is made of human bone tissue obtained from cadavers. The UFTB supplies
significant amounts of such tissue pursuant to an exclusive agreement with the
Company. There can be no assurance that the supply of bone tissue will continue
to meet current demand, or that the Company, if required, will be able to locate
alternative sources of human bone tissue on a timely and cost-effective basis.
To date, constrained supply of human bone tissue has limited growth in this
area. There can be no assurance that the UFTB will meet the Company's future
delivery requirements of human bone tissue. The inability to procure an adequate
supply of such tissue could have a material adverse effect on the Company's
business, financial condition and results of operations.

POSSIBLE VOLATILITY OF STOCK PRICE

The market prices for securities of medical device companies historically have
been highly volatile. Announcements of technological innovations or new products
by the Company or its competitors, developments concerning litigation matters
and proprietary rights, including patents, publicity regarding actual or
potential results with respect to products under development by the Company or
others, regulatory developments in both the United States and foreign countries
and public concern as to, among other things, the safety of new technologies,
changes in financial estimates by securities analysts and failure of the Company
to meet such estimates may have a significant impact on the market price of the
Common Stock. In addition, the Company believes that fluctuations in its
operating results may cause the market price of its Common Stock to fluctuate,
perhaps substantially.

POTENTIAL ADVERSE IMPACT OF SHARES ELIGIBLE FOR FUTURE SALE

Sales of a substantial number of shares of Common Stock (including shares
issuable upon the exercise of outstanding options) in the public market after
the Offering could materially and adversely affect the market price of the
Common Stock. Such sales might also make it more difficult for the Company to
sell equity securities or equity related securities in the future at a time and
price that the Company deems appropriate. Following the Offering, 3,219,229
outstanding shares of Common Stock, including 1,206,080 shares issued to the
Selling Shareholders pursuant to the Sofyc Exchange, will be "restricted
securities" as that term is defined in Rule 144 under the Securities Act and
under certain circumstances may be sold without registration pursuant to Rule
144. The holders of approximately 3,068,002 shares of Common Stock will enter
into lock-up agreements (the "Lock-Up Agreements") under which such holders will
agree not to offer, sell or otherwise dispose of such shares for 90 days after
the date of this Prospectus, without the prior consent of J.P. Morgan Securities
Inc. See "Selling Shareholders."

EFFECT OF CERTAIN CHARTER AND BYLAW PROVISIONS

Certain provisions of the Company's Articles of Incorporation and Bylaws may
have the effect of making it difficult for a third party to acquire, or of
discouraging a third party from attempting to acquire, control of the Company.
Such provisions could limit the price that certain investors might be willing to
pay in the future for shares of the Company's Common Stock. Certain of these
provisions will allow the Company to issue Preferred Stock without any vote or
further action by the stockholders or eliminate the right of stockholders to
call special meetings of stockholders. These provisions may make it difficult
for stockholders to take certain corporate actions and could have the effect of
delaying or preventing a change in control of the Company. See "Description of
Capital Stock."

15
17

USE OF PROCEEDS

The net proceeds to the Company from the Offering, after deducting the
underwriting discount and offering expenses payable by the Company, are
estimated (assuming a price to public of $66.063 per share) to be approximately
$75.6 million ($102.2 million if the Underwriters' over-allotment option is
exercised in full). The Company intends to use a portion of the net proceeds to
repay approximately $42.7 million of the outstanding borrowings under the
Company's U.S. revolving line of credit (approximately $60.7 million in
borrowings was outstanding under such line as of February 2, 1998). The
Company's U.S. revolving line of credit matures in July 2000 and the weighted
average interest rate on this line of credit during 1997 was approximately 6.4%.
Borrowings under such line of credit were incurred to finance both working
capital and capital expenditure needs. The balance of such net proceeds will be
used for general corporate purposes, which may include research and product
development, capital expenditures, the scheduled payment pursuant to the
Company's license agreement with Genetics Institute, certain foreign taxes due
in connection with the Sofyc Exchange, acquisitions and working capital. Pending
such application, proceeds not used to repay borrowings under the Company's U.S.
revolving line of credit will be invested in short-term investment grade
instruments, certificates of deposit and direct and guaranteed obligations of
the United States of America. The Company will not receive any proceeds from the
sale of the Common Stock offered by the Selling Shareholders.

PRICE RANGE OF COMMON STOCK AND DIVIDEND POLICY

The Company's Common Stock is traded on the NYSE under the symbol "SDG." The
following table sets forth the high and low closing sale price per share of the
Common Stock, as quoted on the NYSE, for the periods presented.

-------------------
HIGH LOW
------- -------

YEAR ENDED DECEMBER 31, 1996
First Quarter........................................................................ $35.500 $24.000
Second Quarter....................................................................... $36.875 $25.250
Third Quarter........................................................................ $30.875 $21.625
Fourth Quarter....................................................................... $32.625 $24.750
YEAR ENDED DECEMBER 31, 1997
First Quarter........................................................................ $43.750 $30.750
Second Quarter....................................................................... $47.125 $35.500
Third Quarter........................................................................ $57.125 $44.125
Fourth Quarter....................................................................... $73.188 $56.625
YEAR ENDING DECEMBER 31, 1998
First Quarter (through February 2)................................................... $66.063 $61.250

On February 2, 1998, the reported closing sale price of the Common Stock on the
NYSE was $66.063 per share. As of January 22, 1998, there were 864 holders of
record of the Company's Common Stock. See "Risk Factors -- Possible Volatility
of Stock Price."

The Company has never declared or paid dividends on its capital stock and does
not anticipate paying cash dividends in the foreseeable future. The Company
intends to retain any future earnings for use in the operations, development and
growth of its business.

16
18

CAPITALIZATION

The following table sets forth the short-term debt and consolidated
capitalization of the Company as of December 31, 1997 (i) on an actual basis and
(ii) as adjusted to give effect to the Sofyc Exchange and to the sale by the
Company of 1,200,000 shares of Common Stock offered hereby (at an assumed price
to public of $66.063 per share) and the use of a portion of the net proceeds to
the Company from the Offering to repay borrowings under the Company's U.S.
revolving line of credit. This table should be read in conjunction with
"Management's Discussion and Analysis of Financial Condition and Results of
Operations" and the Consolidated Financial Statements and Notes thereto included
elsewhere and incorporated by reference in this Prospectus.

------------------------
AT DECEMBER 31, 1997
------------------------
ACTUAL AS ADJUSTED
-------- -----------
In thousands

Short-term debt
Notes payable and lines of credit............................................... $ 11,731 $ 11,731
Current maturities of long-term debt............................................ 7,586 7,586
-------- --------
Total short-term debt................................................... $ 19,317 $ 19,317
======== ========

Long-term debt, less current maturities........................................... $ 60,650 $ 23,100
-------- --------
Minority interest................................................................. 3,171 3,171
Stockholders' equity:
Preferred stock, no par value, 5,000,000 shares authorized; no shares
outstanding.................................................................. -- --
Common stock, no par value, 150,000,000 shares authorized; 25,867,749 shares
issued (29,873,829 shares as adjusted)(1).................................... 74,014 322,893
Retained earnings............................................................... 154,828 154,828
Cumulative translation adjustment............................................... (4,294) (4,294)
Less:
Cost of common stock held in treasury, 685,908 shares (4,023,180 shares as
adjusted).................................................................... (9,985) (185,185)
Stockholder notes receivable.................................................... (3,265) (3,265)
-------- --------
Total stockholders' equity................................................... 211,298 284,977(2)
-------- --------
Total capitalization.................................................... $275,119 $ 311,248
======== ========

- ---------------

(1) Excludes (i) 5,304,761 shares of Common Stock issuable upon exercise of
outstanding stock options (of which options to purchase 1,380,345 shares were
currently exercisable) and (ii) 1,786,307 shares reserved for options that may
be granted in the future under the Company's stock plans.

(2) The Company presently expects that in 1998 it will cancel the 3,337,272
shares of Common Stock which will be held in treasury as a result of the Sofyc
Exchange. Such cancellation would require the payment of approximately $10.5
million of foreign taxes, which would result in a reduction of total
stockholders' equity in the same amount. The cancellation will have no impact on
the Company's Consolidated Statement of Income.

17
19

SELECTED CONSOLIDATED FINANCIAL DATA

The selected consolidated financial data set forth below has been derived from
the Consolidated Financial Statements of the Company and Notes thereto audited
by Coopers & Lybrand L.L.P., independent public accountants. Such data is
qualified in its entirety by, and should be read in conjunction with,
"Management's Discussion and Analysis of Financial Condition and Results of
Operations" included elsewhere in this Prospectus as well as with the other
information set forth and incorporated by reference in this Prospectus.

---------------------------------------------
YEAR ENDED DECEMBER 31,
----------------------------------------------------
In thousands, except per share data 1997 1996 1995 1994 1993
-------- -------- -------- -------- --------

STATEMENTS OF INCOME DATA:
Revenues................................................................... $312,902 $244,525 $188,799 $161,677 $161,794
Cost of goods sold......................................................... 58,068 45,005 40,309 35,295 35,893
-------- -------- -------- -------- --------
Gross profit............................................................... 254,834 199,520 148,490 126,382 125,901
Operating expenses:
Selling, general and administrative...................................... 145,414 116,729 89,847 74,183 67,844
Research and development................................................. 19,747 15,926 13,980 11,572 11,488
License agreement acquisition charge..................................... -- -- 45,337 -- --
Product liability litigation charge...................................... -- 50,000 -- -- --
Royalty expenses discontinued subsequent to the combination ............. --...... -- -- -- 1,182
Distributor contract termination charge and related amortization of
short-term intangibles................................................. -- -- -- 10,000 --
-------- -------- -------- -------- --------
Total operating expenses................................................... 165,161 182,655 149,164 95,755 80,514
-------- -------- -------- -------- --------
Income (loss) from operations.............................................. 89,673 16,865 (674) 30,627 45,387
Other income (expense)..................................................... 5 913 2,533 2,153 (179)
Interest expense........................................................... (5,539) (3,744) (2,794) (629) (193)
Combination expense........................................................ -- -- -- -- (9,958)
Non-recurring litigation award............................................. -- -- -- (2,225) --
-------- -------- -------- -------- --------
Income (loss) from continuing operations before provision (benefit) for and
charge in lieu of income taxes and minority interest..................... 84,139 14,034 (935) 29,926 35,057
Provision (benefit) for and charge in lieu of income taxes ................ 25,073 1,293 (6,319) 6,052 14,429
-------- -------- -------- -------- --------
Income before loss from operations of discontinued segment and minority
interest................................................................. 59,066 12,741 5,384 23,874 20,628
Loss from operations of discontinued segment............................... -- -- -- -- (153)
Minority interest.......................................................... (2,282) (1,474) (417) (97) (50)
-------- -------- -------- -------- --------
Net income................................................................. $ 56,784 $ 11,267 $ 4,967 $ 23,777 $ 20,425
======== ======== ======== ======== ========
Net income per share -- diluted............................................ $ 2.12 $ 0.44 $ 0.20 $ 0.97 $ 0.83
Net income per share -- basic.............................................. 2.29 0.46 0.21 0.99 0.85
======== ======== ======== ======== ========
Weighted average number of shares -- diluted............................... 26,783 26,046 25,216 24,496 24,499
Weighted average number of shares -- basic................................. 24,797 24,284 23,846 24,014 24,133
======== ======== ======== ======== ========

---------------------------------------------
AT DECEMBER 31,
----------------------------------------------------
In thousands 1997 1996 1995 1994 1993
-------- -------- -------- -------- --------

BALANCE SHEET DATA:
Working capital............................................................ $122,992 $ 31,127 $ 77,139 $ 69,164 $ 59,441
Total assets............................................................... 385,657 319,161 196,613 141,792 120,597
Short-term debt............................................................ 19,317 66,894 16,602 3,949 1,334
Long-term debt............................................................. 60,650 12,300 28,125 5,324 1,103
Stockholders' equity....................................................... 211,298 139,826 122,929 111,456 92,806

18
20

MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Except for the historical information, the matters discussed herein are
forward-looking in nature and involve risks and uncertainties. The Company's
actual results may differ significantly from the results discussed in
forward-looking statements. Factors that might cause or contribute to such
differences include, but are not limited to, those discussed in "Risk Factors."
References contained herein to the Consolidated Financial Statements refer to
those included in the Company's Current Report on Form 8-K, dated February 3,
1998.

OVERVIEW

Sofamor Danek is primarily involved in developing, manufacturing and marketing
devices, instruments, computer-assisted visualization products and biomaterials
used in the treatment of spinal and cranial disorders. During 1997, the Company
attained record revenues. The Company has increased revenues through growth in
existing businesses and the establishment of direct sales and marketing
operations in key international countries, as well as the development and
strategic acquisitions of complementary products and technologies. International
revenues were $101.5 million and $82.3 million, representing approximately 32%
and 34% of total revenues in 1997 and 1996, respectively. The following table
sets forth, for the periods indicated, selected financial information expressed
as a percentage of revenues and the period-to-period percentage changes in such
information.

-------------------------------------------------------------
AS A PERCENTAGE OF
REVENUES PERIOD-TO-PERIOD CHANGE
YEAR ENDED DECEMBER 31, YEAR ENDED DECEMBER 31,
------------------------- -------------------------------
1997 1996 1995 1997 VS. 1996 1996 VS. 1995
----- ----- ----- ------------- -------------

Revenues.......................................... 100.0% 100.0% 100.0% 28.0% 29.5%
Cost of goods sold................................ 18.6 18.4 21.4 29.0 11.7
----- ----- ----- ------- -------
Gross profit...................................... 81.4 81.6 78.6 27.7 34.4
Operating expenses:
Selling, general and administrative............. 46.4 47.7 47.6 24.6 29.9
Research and development........................ 6.3 6.5 7.4 24.0 13.9
License agreement acquisition charge............ -- -- 24.0 -- (100.0)
Product liability litigation charge............. -- 20.5 -- (100.0) 100.0
----- ----- ----- ------- -------
Total operating expenses.......................... 52.7 74.7 79.0 (9.6) 22.5
Income (loss) from operations..................... 28.7 6.9 (0.4) 431.8 2,602.2
Other income...................................... -- 0.4 1.3 (99.5) (64.0)
Interest expense.................................. (1.8) (1.6) (1.4) 47.9 34.0
----- ----- ----- ------- -------
Income (loss) before provision (benefit) for and
charge in lieu of income taxes and minority
interest........................................ 26.9 5.7 (0.5) 499.5 1,601.0
Provision (benefit) for and charge in lieu of
income taxes.................................... 8.0 0.5 (3.3) 1,839.1 120.5
----- ----- ----- ------- -------
Income before minority interest................... 18.9 5.2 2.8 363.6 136.6
Minority interest................................. (0.7) (0.6) (0.2) 54.8 253.5
----- ----- ----- ------- -------
Net income........................................ 18.2% 4.6% 2.6% 404.0% 126.8%
===== ===== ===== ======= =======

19
21

RESULTS OF OPERATIONS

Years ended December 31, 1997 and 1996

The Company reported revenues for 1997 of $312.9 million, which represented a
$68.4 million, or 28.0%, increase over 1996 revenues of $244.5 million. The
record 1997 revenues reflect the Company's position as the leader in providing
products to treat spinal disorders. Increased volume generated growth of 26.1%.
Revenues were higher by 3.6% due to net changes in pricing and by 2.0% as a
result of the Company's conversion of certain portions of its international
distribution network to direct sales which resulted in higher selling prices. If
exchange rates had been constant, revenues would have reflected an additional
3.7% increase compared with the prior year.

U.S. revenues increased 30.3% to $211.4 million compared with $162.2 million in
1996. The Company believes the improvement in U.S. revenues is primarily the
result of the increasing number of instrumented spinal fusions. The increase in
the number of instrumented fusions has occurred, in part, due to the broad range
of quality spinal products provided by the Company to assist physicians in
treating their patients. In addition to this broad range of implant products,
the Company is benefiting from offering complimentary product technologies
including the STEALTHSTATION(TM) system, the MEDNEXT(R) surgical drill system
and the MED(TM) system. The Company has also benefited from service fees related
to cortical bone dowel and other allograft bone products.

Non-U.S. revenues advanced 23.4% to $101.5 million compared with $82.3 million
in 1996. If exchange rates had been constant, the international revenue growth
over 1996 would have been 34.4%. Higher sales volume in core products and the
acceptance of new products were the primary sources of the increase in revenues
over the prior year. In addition, the Company's revenues continued to benefit
from the direct sales operations which were established in selected countries
during 1996 and 1997.

The Company's gross margin was 81.4% in 1997 compared with 81.6% in 1996. The
slight decrease was primarily attributable to the effects of changes in product
mix.

Selling, general and administrative ("SG&A") expenses expressed as a percentage
of revenues decreased to 46.4% in 1997 compared with 47.7% in 1996. The decrease
in SG&A expenses as a percentage of revenues resulted from the leveraging of
fixed costs over greater revenue volume, despite higher expenses incurred in
direct sales operations established in selected countries during 1996 and 1997.

Research and development expenses totaled $19.7 million, or 6.3% of revenues, in
1997 compared with $15.9 million, or 6.5% of revenues, in 1996. The 1997 dollar
spending represented an increase of 24.0% over 1996. These development and
clinical costs are incurred as the Company continues to enhance existing product
lines and develop new and complementary products, such as the interbody fusion
devices, biological products for use in spinal applications, and products
related to frameless stereotactic surgery in the spinal and neurological fields
of use.

During 1996, the Company recorded a special product liability litigation charge
of $50.0 million. This charge was recorded in order to recognize the reasonably
anticipated costs associated with the defense and conclusion of certain product
liability cases in which the Company is named as defendant. No such charge was
recorded in 1997. The Company believes that these lawsuits are without merit and
unfounded. (See Note 14 to the Consolidated Financial Statements.)

The Company reported net other income of $5,000 in 1997 compared with $913,000
during 1996. Other income was higher during 1996 due mainly to foreign exchange
gains. Interest expense was $5.5 million in 1997, representing a $1.8 million
increase over 1996. Interest expense was higher during 1997 due to interest on
increased borrowings under the Company's credit facilities occurring principally
as a result of acquisitions made in 1996.

The Company recorded income tax expense of $25.1 million in 1997 and $1.3
million in 1996. The difference between the Company's effective and statutory
tax rates for both 1997 and 1996 resulted primarily from the impact of certain
elections made for U.S. tax purposes following the combination (the
"Combination") of Danek Group, Inc. with Sofamor S.A., and the subsequent
reorganization of Sofamor S.A. from a Societe Anonyme (S.A.) under French law to
a Societe en Nom Collectif (S.N.C.) in late 1993. Management cannot be certain
that such a favorable effective income tax rate will be achieved in future
periods, since the effective tax rate calculation is dependent upon the
Company's pre-tax income dollar amount. Higher future pre-tax income could lead
to higher future effective tax rates. At December 31, 1997, the balance sheet of
the Company reflected a net deferred tax asset of $39.4 million. No valuation
allowance was recorded since sufficient taxable income exists in available
carryback periods to recognize fully these net deferred tax assets. (See Note 11
to the Consolidated Financial Statements.)

Minority interest was $2.3 million in 1997 compared with $1.5 million in 1996.
The increase was primarily related to the existence of a minority interest for a
full year in the Company's Korean subsidiary which was formed in November 1996.

The Company believes that historically inflation has not had a material impact
on its business.

20
22

Years ended December 31, 1996 and 1995

The Company achieved record revenues during 1996 of $244.5 million, which
represented a $55.7 million, or 29.5%, increase over revenues of $188.8 million
in 1995. Revenue growth included an increase of 8.5% that resulted from the
conversion of certain portions of the Company's international distribution
network to direct sales, which resulted in higher selling prices. Other net
pricing changes in existing distribution channels resulted in a 3.9% increase in
revenues. Additional volume comprised the remainder of the increase in revenues.
Changes in exchange rates had an immaterial impact on revenues when comparing
the Company's 1996 revenues with 1995.

U.S. revenues increased 28.4% to $162.2 million, as compared with $126.3 million
in 1995. The Company believes the improvement in U.S. revenues was primarily the
result of an increased number of instrumented fusions, as well as the acceptance
of new products such as the STEALTHSTATION(TM) system, the TIMESH(TM) cranial
plating system and the MEDNEXT(R) surgical drill system.

Non-U.S. revenues increased 31.7% to $82.3 million, as compared with $62.5
million in 1995. The strong international revenue growth during 1996 reflects
the Company's strategy of establishing a direct sales presence in selected
countries and the acceptance of the new products mentioned in the preceding
paragraph, as well as enhanced international sales and marketing programs.

The Company's gross margin improved to 81.6% in 1996 from 78.6% in 1995. The
enhancement in gross margin is due to higher margins relating to changes in
international distribution, greater leveraging of manufacturing costs due to
increased volume, a reduction in the levels of outsourced product manufacturing
and favorable shifts in the sales mix of certain products and sales programs.

SG&A expenses were 47.7% of revenues in 1996 compared with 47.6% of revenues in
1995. The 1996 SG&A expenses as a percentage of revenues compared to 1995 were
slightly higher due to the effects of expenses related to establishing a direct
sales presence in selected countries. These higher expenses were mostly offset
by the leveraging of other fixed costs over greater volume in existing
operations.

Research and development expenses totaled $15.9 million or 6.5% of revenues in
1996 compared with $14.0 million or 7.4% of revenues in 1995. The 1996 dollar
spending represented an increase of 13.9% over 1995. These costs were incurred
as the Company continued to enhance existing product lines and develop new and
complementary products for use in spinal surgery, such as interbody fusion
devices, biological products for use in spinal reconstruction and products
related to frameless stereotactic surgery in the spinal and neurological fields
of use.

During 1996, the Company recorded a special product liability litigation charge
of $50.0 million. This charge was recorded in order to recognize the reasonably
anticipated costs associated with the defense and conclusion of certain product
liability cases in which the Company is named as defendant. The Company believes
that these lawsuits are without merit and unfounded. (See Note 14 to the
Consolidated Financial Statements.)

In 1995, the Company entered into a strategic alliance with Genetics Institute
to provide biological products for use in spinal applications (the "G.I.
Agreement"). Pursuant to the G.I. Agreement, the Company obtained exclusive
North American rights to recombinant human bone morphogenetic protein (rhBMP-2)
for spinal applications. As a result of the G.I. Agreement, a special charge of
$45.3 million was recorded. The special charge consisted of $45.2 million, which
represented the net present value of the $50.0 million in scheduled payments due
under the agreement, plus related transaction costs of $122,000. The charge
resulted in an after-tax impact of $1.16 per diluted share for the year ended
December 31, 1995.

The Company reported net other income of $913,000 in 1996 compared with $2.5
million during 1995. Other income was higher during 1995 due mainly to the
reversal of certain risk provisions and greater foreign exchange gains. Interest
expense was $3.7 million in 1996, representing a $950,000 increase over 1995.
The increase in interest expense was due to increased borrowings under the
Company's credit facilities occurring principally as a result of the
acquisitions made during 1996.

The Company recorded income tax expense of $1.3 million in 1996 and an income
tax benefit of $6.3 million in 1995. The difference between the Company's
effective and statutory tax rates for both 1996 and 1995 resulted primarily from
the impact of certain elections made for U.S. tax purposes following the
Combination of Danek Group, Inc. with Sofamor S.A., and the subsequent
reorganization of Sofamor S.A. from an S.A. under French law to an S.N.C. in
late 1993.

Minority interest was $1.5 million in 1996 compared with $417,000 in 1995. The
increase was principally due to the minority interest in the Company's Japanese
subsidiary which was formed in February 1996.

21
23

LIQUIDITY AND CAPITAL RESOURCES

On January 26, 1998, the Company purchased all of the outstanding capital stock
of Sofyc for an aggregate of 2,806,080 privately placed shares of the Company's
Common Stock, $1.0 million in cash (less certain expenses relating to the
repurchase) and the Company's agreement to repay certain outstanding loans of
Sofyc equal to approximately $925,000. Sofyc, which was the personal holding
company of the Cotrel family, owns 3,337,272 shares of the Company's Common
Stock. As a result of the Sofyc Exchange, the outstanding shares of Common Stock
of the Company will be reduced by 531,192 shares.

Cash generated from operations and the Company's revolving lines of credit are
the principal ongoing sources of funding available for growth of the business,
including working capital and additions to property, plant and equipment, as
well as debt service requirements and required contractual payments. The Company
believes that these sources of funding together with the proceeds from the
Offering will be sufficient to meet its expected cash needs for the foreseeable
future. Cash, cash equivalents and short-term investments totaled $2.8 million
at December 31, 1997, compared with $2.9 million at December 31, 1996.

The Company's working capital increased by $91.9 million during 1997. The
increase in working capital resulted primarily from the renegotiation of the
Company's $100.0 million uncollateralized revolving line of credit with a
syndicate of U.S. banks which extended the maturity thereof from October 1997 to
July 2000 (see Notes 8 and 9 to the Consolidated Financial Statements) as well
as the effects of operating activities. Accounts receivable increased $18.2
million or 26.0% from December 31, 1996, due principally to the 30.2% increase
in revenues in the fourth quarter of 1997 compared with the last quarter of
1996. Inventories and loaner set inventories increased by $14.5 million from
prior year, due mostly to stocking levels required for recently formed
subsidiaries and the production of inventories in preparation for new sales and
marketing programs. Other receivables, which consisted primarily of amounts
recoverable from insurance carriers related to the costs incurred in connection
with product liability litigation (see Note 14 to the Consolidated Financial
Statements), increased $13.6 million from the previous year-end.

In connection with the formation of its subsidiary in Japan, Kobayashi Sofamor
Danek, K.K. ("KSD"), the Company is required to pay commissions based on the
sales of KSD to Kobayashi Pharmaceutical Co., Ltd. ("KPC"), which has served as
the Company's distributor in Japan and is the other shareholder in KSD. Payments
of $2.0 million and $26.7 million in 1997 and 1996, respectively, were made to
KPC as prepayments of commissions.

In connection with the G.I. Agreement, the Company has a liability of $7.0
million at December 31, 1997. This liability represents the initial present
value of the remaining $7.5 million payment due in June of 1998 under the
agreement. Under this agreement, payments of $17.5 million, $12.5 million and
$12.5 million were made in 1997, 1996 and 1995, respectively.

The purchase agreements for two acquisitions made by the Company in 1996 contain
provisions which provide for contingent payments to the former shareholders of
each entity based upon certain calculations relative to revenues and earnings,
as defined, through 1999. Such payments are reflected as purchase price
adjustments. The Company recorded adjustments to the purchase price of these
acquisitions of $5.1 million and $4.2 million in 1997, and 1996, respectively.
The amount recorded in 1996 was paid in April 1997, and the amount recorded in
1997 is expected to be paid in March 1998. The Company is unable to determine
whether such adjustments will be required for 1998 or 1999.

Additions to property, plant and equipment amounting to $10.3 million, $7.1
million and $4.6 million in 1997, 1996 and 1995, respectively, were made
primarily relating to capital assets acquired in the formation and acquisition
of new subsidiaries and other capital expenditures necessary to support the
Company's manufacturing and distribution operations. The Company is in need of
additional office and distribution space at its Memphis location. Management has
entered into an agreement whereby the Company will lease, with an initial term
of 10 years, a new facility adjacent to its existing headquarters with an
expected occupancy date of mid 1998. This lease will be accounted for as an
operating lease.

The Company has committed lines of credit totaling $115.9 million. At December
31, 1997, $67.3 million was outstanding under these lines of credit and other
short-term borrowings. The committed lines of credit consist primarily of the
$100.0 million U.S. revolving line of credit.

In 1996, the Internal Revenue Service began an examination of the Company's
federal income tax returns. The years under examination are 1993, 1994 and 1995.
Management believes that the resolution of any issues that may be developed as a
result of the examination will not have a significant impact on the Company's
results of operations or financial condition.

The Company invests available funds in short-term investment grade instruments,
certificates of deposit or direct or guaranteed obligations of the United States
of America. These short-term investments are available to fund the Company's
working capital requirements and acquisitions of capital assets.

22
24

The "Year 2000" issue is the result of computer programs being written using two
digits rather than four to define the applicable year. Any computer programs
that have time sensitive software may recognize a date using "00" as the year
1900 rather than the year 2000. This could result in a system failure or
miscalculations causing disruptions of operations, including, among other
things, a temporary inability to process transactions, send invoices or engage
in similar normal business activities. Management has conducted an assessment of
its exposure to disruption associated with the "Year 2000" issue. The Company is
currently in the process of implementing purchased software that will serve as
an enterprise resource planning system providing enhanced productivity and
customer service benefits in addition to mitigating potential consequences of
the Year 2000 issue. The cost of the software license and the majority of the
costs of implementation will be capitalized. Management expects this
implementation to be complete by the end of 1998. The Company believes that with
modifications to existing software and conversions to new software, the Year
2000 issue will not pose significant operational problems for its computer
systems. However, if such modifications are not made, or are not completed in a
timely manner, the Year 2000 issue could have an impact on the Company's ability
to operate. The Company does not believe that the costs of addressing this issue
will be material to the Company's operations.

23
25

BUSINESS

Except for historical information, the matters discussed herein (including, in
particular, those discussed in "-- Legal Proceedings") are forward-looking in
nature and involve risks and uncertainties. The Company's actual results may
differ significantly from the results discussed in forward-looking statements.
Factors that might cause or contribute to such differences include, but are not
limited to, those discussed in "Risk Factors."

OVERVIEW OF THE COMPANY

Sofamor Danek is primarily involved in developing, manufacturing and marketing
devices, instruments, computer-assisted visualization products and biomaterials
used in the treatment of spinal and cranial disorders. In 1997, the Company had
an approximately 50% market share of the worldwide spinal implant market, a
rapidly growing market which exceeded $500 million in worldwide sales. In
addition to its leadership position in the spinal implant market, the Company
provides a comprehensive line of products for the spinal surgeon and
neurosurgeon, including the STEALTHSTATION(TM) (an image-guided surgical
system), the MED System for minimally invasive discectomies, MEDNEXT(R) high
speed drills and TIMESH(TM) cranial plates. As of December 31, 1997, the Company
had a total of 150 510(k) Clearances for spinal and neurosurgical products. The
Company also has a broad pipeline of spinal and neurosurgical products under
development to augment its existing product offerings and further advance the
state of the art of surgical and diagnostic procedures. Key products under
development include the Novus line of threaded interbody fusion devices,
including the Novus Cage, which is currently being marketed for use in certain
non-U.S. countries. Other key products under development include biological
products to induce bone growth, prosthetic discs and products utilizing
visualization technology to aid surgeons. The Company has 300 patents and patent
applications in the United States. For the year ended December 31, 1997, the
Company generated $312.9 million in revenues and $56.8 million in net income.

BUSINESS STRATEGY

The Company's business strategy is to design, develop, manufacture and market a
broad range of innovative implant devices and surgical systems for head, neck
and spine surgery. The Company leverages its technology and engineering
expertise to enhance its existing products and develop new products to serve the
needs of spinal surgeons and neurosurgeons. The Company's marketing strategy is
to provide differentiated products, service and support to spinal surgeons and
neurosurgeons through its direct sales presence in all major markets worldwide.
The Company utilizes its relationships with leading physicians to increase
acceptance of the Company's products, promote physician training and education
and obtain physician feedback for new product development. The Company also
plans to continue to leverage its marketing infrastructure by developing,
licensing, or acquiring other surgical products that serve the Company's
existing customer base of spinal surgeons and neurosurgeons. Examples of product
line additions which have application outside of spinal surgery include:

- - STEALTHSTATION(TM) for image guided surgery and Vista head mounted display and
3-D imaging systems which are intended to be used in spinal and neurological
procedures. The Company believes that future uses of these systems will
include radiosurgery, complex fractures and total joint replacement.

- - TiMesh's product line, which include titanium plates and screws used in
neurological procedures.

- - MedNext's product line consisting of high speed pneumatic drills, accessory
equipment and disposable burrs serving spinal surgeons and neurosurgeons.

- - MED System for removing disc material in a minimally invasive manner.

INDUSTRY OVERVIEW

Spinal implants are a rapidly growing market segment, generating in excess of
$500 million in worldwide sales in 1997. Spinal implants are often used to
alleviate chronic back pain, which, in the United States, is the leading cause
of workman's compensation expense, the second leading cause of physician office
visits and the third leading reason for surgical procedures. The objective of
spinal implants in a fusion procedure is to increase spinal stability and
facilitate fusion of two or more vertebrae in the spine. The goal of fusion is
to relieve back pain by alleviating pressure on nerves that run through the
spinal column by permanently prohibiting movement between vertebrae.

The spine is essentially made up of vertebrae with discs between each vertebrae.
These intervertebral discs provide the proper spacing between the vertebrae and
allow for movement between vertebrae. When the intervertebral discs degenerate,
are deformed or are injured and begin to collapse, the spinal column begins to
compress and the vertebrae put pressure on the nerves that run through the
spinal column resulting in pain. In a spinal fusion procedure, bone graft is
usually implanted

24
26

between the vertebrae so that bone will grow between the vertebrae and thereby
fuse the vertebrae together. If fusion is achieved, the vertebrae will be
immobilized, the proper spacing between vertebrae will be achieved relieving the
pressure on the nerves that run through the spinal column.

Spinal fusions are performed to treat diseases and conditions such as
degenerative diseases, deformities and trauma. Degenerative diseases of the
spine typically occur in mature adults and can result in immobility, pinched
nerves and chronic pain for the patient. Deformities, unless treated at a young
age, can prevent proper growth of the spine and can be life threatening if
allowed to progress. Traumatic injuries to the spine are typically the result of
automobile accidents. A surgeon's decision to treat a spinal condition with an
implant is based on many factors, including the relative severity of the
patient's condition, such as the degree of the curvature of the spine, the age
of the patient, the patient's medical history and the physical condition of the
patient (i.e., the ability to withstand surgery).

Spinal fusion procedures can be performed with or without instruments or fusion
devices. Until the mid-1980's, surgeons had limited implant options for treating
spinal conditions. Surgeons treating spinal conditions either did so without
implants or utilized basic implant devices. These devices often did not
sufficiently immobilize the spine and thus limited the fusion rate and efficacy
of the procedures. In seeking better alternatives for spinal fusions, surgeons
began to use implants designed primarily to provide greater structural support
for the spine and enhance the healing process. Over the last several years,
clinical studies have shown that surgeries using spinal implants are more
effective in immobilizing the spine than surgeries in which implants are not
used.

Traditional spinal implant devices use rods, bolts, hooks, plates, screws and
other similar devices to immobilize and stabilize a portion of the spine in
order to facilitate fusion. The newest development in spinal implant devices
involves the use of an interbody fusion device commonly referred to as a fusion
cage. Fusion cages are hollow cylinders which are implanted into the space
between successive vertebrae and may be made of metal (such as titanium), may be
threaded and are filled with bone graft. The goal of a fusion cage is for the
successive vertebrae to fuse, or grow with the fusion cage, thereby permanently
prohibiting movement between these vertebrae.

In 1996, there were approximately 225,000 spinal fusion procedures (both
instrumented and non-instrumented) done in the United States and approximately
235,000 spinal fusion procedures done internationally. In recent years,
worldwide spinal fusion procedures involving the cervical, thoracic and lumbar
regions of the spine have been approximately 45%, 15% and 40%, respectively, of
the total worldwide spinal fusion market. In 1996, while between 95% and 100% of
worldwide thoracic spinal fusion procedures were instrumented, only 30% of U.S.
cervical spinal fusion procedures were instrumented. In the lumbar spinal fusion
procedure market, the only market where fusion cages are used, approximately 55%
of these procedures were instrumented in the United States in 1996.

SPINAL AND NEUROSURGICAL PRODUCTS

Spinal Implant Instrumentation and Threaded Cortical Bone Dowels

The objective of spinal implants is to increase spinal stability and facilitate
fusion of the vertebrae of the spine. The Company's spinal systems include the
TSRH(R) Spinal System, the CD(TM) line of products and the ORION(TM) System.
These lines of surgical implants include tools for fusion such as rods, plates,
screws, hooks, locking bolts and transverse traction devices that lock implants
together. The Company markets products which treat degenerative diseases,
deformities and trauma in all regions of the spine. Spinal surgeons and
neurosurgeons choose a spinal implant system based on, among other things, the
nature and location of the spinal instability. The Company currently markets
approximately 33 spinal implant product lines. In addition, the Company markets
the Novus Cage in non-U.S. countries and is currently seeking FDA approval to
market the product in the United States. In 1996, the Company began
distributing, on behalf of the UFTB, threaded Cortical Bone Dowels, a product
that is made of human bone. Spinal implant products and threaded Cortical Bone
Dowels accounted for $260.5 million, or 83%, of Sofamor Danek's revenues in
1997.

TSRH(R) Spinal System. The TSRH(R) Spinal System traces its origins to research
conducted at the Texas Scottish Rite Hospital in Dallas, Texas and is used
primarily to treat patients afflicted with degenerative diseases, scoliosis
(curvature of the spine) or other spinal deformities. The system consists of
specialized hooks, plates and screws that are attached to rods through locking
bolts, which the Company believes allows for increased torsional and axial
spinal support. There are special configurations of the system available to
address specific applications such as pediatric surgery and adult lumbar
surgery. The Company manufactures and distributes the TSRH(R) Spinal System
under agreements pursuant to which the Company has received the exclusive
worldwide rights to the products in exchange for royalty payments. Sales of the
TSRH(R) Spinal System accounted for 24% of the Company's revenues in 1997, 33%
in 1996 and 38% in 1995.

Since its introduction in 1989, the Company has added enhancements to the
TSRH(R) Spinal System, including the Variable Angle Screw, Central Post Hook,
Lateral Offset Plate, Open Eyebolt and Top Tightening components. The Variable
Angle

25
27

Screw provides flexibility in screw placement in relation to the spinal rod.
Similarly, the Central Post Hook offers versatility in hook placement. The
Lateral Offset Plate allows variations in the lateral distance between a hook or
sacral screw and the spinal rod. The Open Eyebolt can be used when an eyebolt
must be added after all hooks and CROSSLINK(R) plates are in place. The Top
Tightening components incorporate T-bolts, hooks, sacral/iliac screws and
staples into a comprehensive spinal implant system. These enhancements provide
interchangeability of components and improved ease of use for surgeons. The
TSRH(R) Spinal System is covered by various patents.

CD(TM) Line of Products. The Cotrel-Dubousset line of products was developed by
Dr. Yves Paul Cotrel in cooperation with Sofamor and with the assistance of
Professor Jean Dubousset. This product line includes the CD(TM) Spinal
Instrumentation System (the "CD(TM) System"), the Compact CD or CCD(TM) System
(the "CCD(TM) System") and the CD HORIZON(TM) Spinal System (the "CD HORIZON(TM)
System"). The CD(TM) System was introduced in 1984 and was designed primarily to
treat patients afflicted with spinal deformities and fractures of the spine in
the thoracic and lumbar regions. The principal components of the CD(TM) System
include spinal rods, hooks, sacral screws and transverse traction devices which
lock implants together and a wide range of instruments used to position and
secure the implants. The CCD(TM) System was designed principally for the
treatment of degenerative spinal conditions of the lumbar and sacral spine. The
CD HORIZON(TM) System combines new, low profile hooks and screws with components
of several other systems for the treatment of various spinal conditions. Sales
of the Cotrel-Dubousset line of products accounted for 17% of the Company's
revenues in 1997, 23% in 1996 and 26% in 1995.

ORION(TM) System. The ORION(TM) System was introduced by the Company in 1994.
This system is indicated for use in stabilizing the anterior cervical spine
during the development of a solid spinal fusion in patients with degenerative
diseases, traumatic fractures and tumors. The system consists of a plate and
screws which attach to the anterior cervical spine (front part of the neck). The
Company manufactures and distributes the ORION(TM) System under agreements
pursuant to which the Company obtained the exclusive worldwide rights to the
products in exchange for royalty payments. The ORION(TM) System accounted for
11% of the Company's revenues in 1997, 10% in 1996 and 8% in 1995.

Novus Cage. The Company's Novus Cage is a titanium, threaded, hollow,
perforated cylinder that is packed with bone graft and implanted into the disc
space between the vertebrae. The Novus Cage is designed to facilitate spinal
fusion. The Novus Cage is being marketed in certain non-U.S. countries and the
Company is currently seeking FDA approval to market the product in the United
States. Interbody fusion cages currently on the market can be implanted less
invasively than traditional implants and are intended to be used for certain
spinal fusions in the lumbar region of the spine as well as for supporting the
spine after discectomies. In the United States, approximately 400,000
discectomies are performed each year to remove spinal discs. These procedures
historically have not used a significant amount of surgical instrumentation. In
1997, worldwide interbody fusion cage sales for all companies were approximately
$115 million.

Cortical Bone Dowels. The Company distributes threaded Cortical Bone Dowels, a
product made of human bone, in the United States on behalf of UFTB pursuant to
an exclusive agreement.

Surgical Systems

In addition to its leadership position in the spinal implant market, the Company
provides a comprehensive line of products for the spinal surgeon and
neurosurgeon, including the STEALTHSTATION(TM), the MED System, MEDNEXT(R) high
speed drills and TIMESH(TM) cranial plates.

STEALTHSTATION(TM). The STEALTHSTATION(TM) is an advanced computer-assisted,
image-guided surgery system which provides surgeons with the capability to plan,
navigate and precisely position surgical tools and devices during cranial,
spinal, ear, nose and throat procedures. Specifically, the STEALTHSTATION(TM)
allows surgeons to take standard image data sets from practically any image
source (CT, MR, etc.) and transform them into a three-dimensional image.
Surgeons can use the system to plan the most desirable path through critical
anatomy, then move seamlessly into the operating room where this image data is
registered, or matched, to the patient's actual anatomy. Thus, the
STEALTHSTATION(TM) enhances the accuracy of delicate surgical procedures. The
STEALTHSTATION(TM) assists the surgeon by precisely identifying in real-time the
location of a surgical instrument's tip in relation to the patient's
preoperative diagnostic imaging scan. The Company believes that use of the
STEALTHSTATION(TM) system significantly reduces operating room time and the
length of the patient's hospital stay, which has reduced the overall cost of
such procedures. The Company obtained initial FDA marketing clearance for the
STEALTHSTATION(TM)system in January 1996 for use throughout the body. The
Company believes the STEALTHSTATION(TM) has the leading share of the worldwide
frameless stereotactic image-guided surgery market. The Company generates
recurring revenue from this product from annual maintenance contracts, software
upgrades and product enhancements.

26
28

MED System. The Company's MED System, which consists of a large tube (or
trocar), a disposable endoscope, a light source and a video system, allows
surgeons to perform minimally invasive discectomies by making an incision in the
back of the patient and removing all or part of a herniated disc in order to
relieve pressure on the spinal cord or nerve root. The ability to perform a
discectomy endoscopically using the MED System may eliminate the need for
general anesthesia. This procedure can be performed in an outpatient setting, as
opposed to requiring a hospital stay of approximately three days. The Company
believes the procedure also reduces patient recovery time, post-operative pain
and narcotic use. In 1997, there were approximately 400,000 discectomy
procedures performed in the United States.

Other Products

The Company's other products include the TIMESH(TM) cranial plating system and
the MEDNEXT(R) surgical drill system. The TIMESH(TM) system offers a unique
high-torque screw design with a thread-cutting feature, along with plates and
mesh, all made of commercially pure titanium, specially treated to optimize
biocompatibility and provide malleability. The MEDNEXT(R) system consists of a
high speed pneumatic drill, accessory equipment and disposable dissecting burrs
and is used in cranial and microendoscopic discectomy procedures.

RECENT ACQUISITIONS AND ALLIANCES

In December 1997, the Company acquired certain net assets of MAN Ceramics, a
subsidiary of the MAN Group of Munich. MAN Ceramics designs, manufactures and
markets carbon fiber interbody fusion devices. The single filament carbon fiber
is transparent in most types of imaging and has an elasticity that is closer to
bone than to other currently used implant materials. Clinical studies in Europe
included the testing of more than 1,400 devices over the past five years. FDA
approval will be required in order to market the product in the United States.

In January 1998, the Company entered into an exclusive, renewable five-year
strategic alliance with Vista to develop and distribute advanced visualization
systems based on Vista's proprietary head mounted display and 3-D image
acquisition technology for head, neck and spine procedures. Pursuant to this
alliance, the Company will distribute the Stereo-Site visualization and
information products of Vista's Head, Neck and Spine Microsurgery Division.

RESEARCH AND PRODUCT DEVELOPMENT

In addition to its currently marketed products, the Company has a broad pipeline
of spinal and neurosurgical products under development to augment its existing
product offerings and further advance the state of the art of surgical and
diagnostic procedures. Key products under development include the Novus Cage,
which is an interbody fusion device approved for use in certain non-U.S.
countries, biological products to induce bone growth, prosthetic discs and
visualization technology to aid surgeons. The Company incurred research and
development expense of approximately $19.7 million, $15.9 million and $14.0
million for the years ended December 31, 1997, 1996 and 1995, respectively.

Biological Products for Use in Spinal Reconstruction

In February 1995, the Company entered into a strategic alliance with Genetics
Institute to develop biological products for use in spinal applications. These
products are being designed to use Genetics Institute's recombinant human bone
morphogenetic protein rhBMP-2 to induce bone growth for the treatment of spinal
disorders and replace the current therapy, which is transplantation of bone
tissue from the pelvis of the patient. The Company has completed an FDA approved
pilot study in which all 11 patients achieved fusion in three months. Typically,
fusion can take between 15 to 18 months to occur. The Company is currently
submitting an IDE to conduct a pivotal study with respect to rhBMP-2. The
Company has obtained exclusive North American rights to these rhBMP-2
proprietary technologies and patents for spinal applications. Pursuant to the
terms of the license agreement, the Company will pay the Genetics Institute $50
million over four years, of which $12.5 million was paid in each of 1995 and
1996 and $17.5 million was paid in 1997. An additional $7.5 million is due in
1998. FDA review and approval, which will require the conduct of clinical
trials, will also be necessary to market these biological products. The Company
will purchase the rhBMP-2 product from Genetics Institute. The Company is
considering a variety of different carriers for the Genetics Institute proteins.
One potential carrier is a porous polymer to which the Company has obtained
worldwide rights under an exclusive license. If this porous polymer carrier is
utilized with rhBMP-2, royalty payments will be due to the owner of the polymer
technology. See "Risk Factors -- Uncertainty of Regulatory Clearances;
Regulatory Compliance" and "-- Dependence on Patents and Proprietary
Technology."

27
29

Novus Cage

In addition to the cages that it currently markets, the Company is developing a
wide variety of products that the Company believes will more effectively meet
patient needs in the cage segment. These products include cages designed to more
accurately match the anatomy of the spine to ease insertion and conserve the
patient's bone. These products will utilize materials that are designed to
better match the characteristics of bone and/or allow the bone to better
incorporate into the implant. The Company has also entered into a licensing
agreement for the worldwide rights to these patented technologies covering
implants, instruments and methodologies for simultaneously performing a
discectomy, a fusion and an internal stabilization of the spine.

Prosthetic Disc Program

The Company is actively evaluating various designs for the replacement of
diseased and/or damaged discs. These designs are at various stages of
development and would ultimately require pre-market approval by the FDA prior to
marketing in the United States.

Visualization Technologies

In January 1998, the Company entered into a cooperative technology agreement
with Vista to develop and distribute new advanced visualization systems based on
Vista's proprietary high resolution digital technology. Pursuant to the
agreement, the Company will have the worldwide distribution rights to these new
products for use in neurosurgery, spinal surgery and otolaryngological surgery.

There can be no assurances that the products described above in this section
will be marketed or that FDA authorization will be received. Spinal implants,
image guidance and other related devices are typically rendered obsolete within
a few years. While the Company maintains active research and development
programs, there can be no assurance that it will be able to develop and
introduce new products that will enable it to remain competitive in the future.
See "Risk Factors--Rapid Technological Change and Risk of Technological
Obsolescence."

MARKETING AND DISTRIBUTION

Sofamor Danek markets its spinal implant and surgical systems products in the
United States directly to the spinal surgeons and neurosurgeons who perform
spinal and cranial surgery. The Company distributes its products through its
unique network of approximately 200 commissioned, dedicated sales
representatives. The Company markets its products internationally directly to
spinal surgeons and neurosurgeons in major markets including the Benelux region,
France, Germany, Italy, Spain, the United Kingdom, Canada, South Africa, Puerto
Rico, Hong Kong, Japan, Korea, Australia and New Zealand, and indirectly in
approximately 60 other countries through a network of independent distributors
and agents. The Company believes that its distribution capabilities provide it
with significant competitive advantages by facilitating strong relationships
with the physicians, hospitals and clinics that comprise the Company's customer
base. The Company strengthens these relationships by organizing and sponsoring
the education of surgeons through medical symposia, seminars, payor relations
and practice management consulting. In order to meet the needs of hospitals and
clinics, the Company offers instrument and implant purchase alternatives. For
example, the Company offers a "loaner program" whereby a complete implant system
is shipped overnight for next-day surgery. The customer is charged only for the
components used, and a premium over the published list price is charged to
defray the additional cost of the program. The Company's premier distribution
capability also enables it to attract alliance partners who seek its
distribution breadth.

The Company's backlog of firm orders is not considered material to an
understanding of its business.

MANUFACTURING, QUALITY CONTROL AND RAW MATERIALS

The Company's products are manufactured in the United States primarily by the
Company's subsidiary, Warsaw Orthopedic, Inc., which the Company acquired in
1983. The Company's products are also manufactured by its subsidiaries, SNT,
located in Broomfield, Colorado, and MedNext of West Palm Beach, Florida. The
Company believes that its current assets will provide it with sufficient
manufacturing capacity for the future. As a medical device manufacturer, the
Company is subject to the FDA's stringent QSR and regulations as stipulated by
the FDA. The Company has installed computer controlled machinery in its
manufacturing operations, resulting in greater flexibility in the manufacturing
process and enabling the Company to be cost efficient. The Company also utilizes
comprehensive, integrated MIS (management information system) software for
production, planning and scheduling. The Company employs a broad range of
inspection and quality assurance standards. The Company utilizes in-process
testing and inspection methods in the manufacturing process to produce quality
products. The design and

28
30

layout of the Company's manufacturing facilities affords the Company flexibility
to increase production capacity. Outside the United States, product
manufacturing is done primarily by Sofamor in Rang-du-Fliers, France. Some of
the manufacturing outside the United States is performed by subcontractors.
Sofamor has a 33.75% equity investment in one of the subcontractors. See
"--Government Regulation."

Implant grade stainless steel and titanium alloy account for the majority of the
Company's raw material purchases. There are multiple sources from which the
Company may purchase this type of stainless steel and titanium alloy, and it is
available within one to eight months of the time an order is placed. Titanium
alloy provides less MRI (magnetic resonance image) interference during imaging
of the patient during post-operative follow-up.

COMPETITION

The medical device industry is subject to intense competition. The market for
products designed to treat spinal conditions is highly competitive, and the
Company expects competition to increase. Accordingly, the Company's future
success will depend in part on its ability to respond quickly to medical and
technological change and user preferences through the development and
introduction of new products that are of high quality and that address patient
and surgeon requirements and, in part, on its ability to differentiate its
mature products from those of its competitors. Worldwide, there are many firms
producing spinal implant devices, and certain of the Company's competitors
currently manufacture and sell interbody fusion cages that have received 510(k)
Clearance from the FDA. A number of the Company's competitors have greater
financial, research and development, manufacturing and sales and marketing
resources than the Company. The Company's inability to compete effectively
against existing or future competitors would have a material adverse effect on
its business, financial condition and results of operations.

The Company believes that the primary competitive factors in the market for
treatment of spinal disorders include regulatory approvals, clinical and patient
acceptance, post-operative discomfort, ease of use, product performance,
marketing and sales capability and the enforceability of patent and other
proprietary rights. The Company believes that it is, and will continue to be, a
leader with respect to these factors. The Company believes that it successfully
competes based on (i) the quality of the Company's products and their ease and
versatility of use by surgeons, (ii) the introduction of new products and
systems, (iii) the Company's emphasis on research and development, (iv) the
Company's focus on spinal products coupled with a solid infrastructure of
experienced management personnel, (v) the Company's association with spinal
surgeons and neurosurgeons and (vi) the Company's participation, through medical
symposia and seminars, in the education of surgeons in the cleared uses of
implant products. See "Risk Factors--Increasing Competition."

GOVERNMENT REGULATION

In the United States, the Company is subject to regulation by the FDA. FDA
regulations govern the testing, labeling, promotion and sale of medical devices
and require the Company to maintain certain standards and practices with respect
to the manufacturing and labeling of devices, the maintenance of certain records
and medical device reporting. The Company's facilities and records are subject
to FDA inspections.

The FDA is the agency responsible for the regulation of medical devices in the
United States pursuant to the Food, Drug and Cosmetic Act (as amended by the
1976 Medical Devices Amendment), the Safe Medical Devices Act of 1990 (as
amended in 1992), the Food and Drug Administration Modernization Act of 1997,
the regulations promulgated thereunder and guidance documents and instructions
issued by the FDA. In general, prior to entering commercial distribution,
medical devices must undergo FDA review, either pursuant to a 510(k)
notification or a PMA application filed by the manufacturer of the device. A
510(k) notification is a filing submitted to demonstrate that the device in
question and its labeling are "substantially equivalent" to a "legally marketed
device" and its labeling. In contrast, a PMA application must demonstrate that
the device is safe and effective; it is a more complex submission that typically
includes a two-year follow-up of a controlled human clinical study. Factors that
dictate whether a 510(k) notification or a PMA application is required include:
whether the device and its labeling are "substantially equivalent" to a "legally
marketed device" and its labeling. The process of obtaining marketing
authorizations can be time consuming, and there can be no assurance that all the
necessary authorizations will be granted to the Company with respect to new
products and devices developed by the Company.

All of the Company's implants currently marketed in the United States are
covered by 510(k) notifications with limited exceptions, such as custom
implants. As devices become increasingly innovative, it is difficult to
establish that a device is "substantially equivalent" to another "legally
marketed device" and thereby obtain 510(k) Clearance for a new product.
Additionally, as clarified by the Safe Medical Devices Act of 1990, the FDA
could, and generally does, decide to require the submission of additional data.
It is impossible to predict whether additional changes will be made in the
510(k) Clearance

29
31

practices and whether any such changes could have an adverse effect on the
Company and its business. The Company cannot predict the extent or impact of
future federal, state or local legislation or regulation.

If human clinical trials of a device are required and if the device presents a
"significant risk," the manufacturer or distributor of the device is required to
file an IDE application with the FDA prior to commencing human clinical trials.
The IDE application must be supported by data, typically the result of animal,
and, possibly, mechanical testing. If the IDE application is approved by the
FDA, human clinical trials may begin at a specific number of investigational
sites with a maximum number of patients, as approved by the FDA.

Federal law provides that manufacturers can label and promote new medical
devices only for indications that have been allowed by the FDA. Since the FDA
does not regulate the practice of medicine, physicians may use products for
applications that have not yet been cleared by the FDA for such a labeling
indication if such use is deemed in their medical judgment to be in the
patient's best interests. Thus, as part of the practice of medicine, physicians
may at their discretion and in the exercise of their medical judgment use any
legally marketed screws for indications not in the labeling. Although this
practice may continue in the future, the Company does not encourage nor can it
predict such use.

In January 1995, the Company received 510(k) Clearance to begin labeling and
marketing the stainless steel version of the TSRH(R) Spinal System for pedicle
screw attachment only for treating selected patients with grade 3 or 4 severe
spondylolisthesis of the fifth lumbar-first sacral (L5-S1) vertebral joint. The
clearance is based on this spinal system having been found equivalent only to
similar device systems labeled and intended for patients: (a) who have severe
spondylolisthesis (grades 3 and 4) of the fifth lumbar-first sacral (L5-S1)
vertebral joint; (b) who are receiving fusions using autogenous bone graft only;
(c) who are having the device fixed or attached to the lumbar and sacral spine;
and (d) who are having the device removed after the development of a solid
fusion mass. This clearance requires the addition of specific warnings to the
labeling of the product. Since that time, many other systems offered by the
Company have received clearance for similar labeling.

In October 1997, the Company received 510(k) Clearance to begin labeling and
marketing its CD Spinal System with the following restrictions. As a pedicle
screw fixation system, the device system is intended only for: (a) degenerative
disc disease (defined as back pain of discogenic origin with degeneration of the
disc confirmed by patient history and radiographic studies) for noncervical
screw fixation; and (b) for severe spondylolisthesis (Grades 3 and 4) at the
L5-S1 joint in patients who are receiving fusions using autogenous bone graft
only and who are having the device removed after the development of a solid
fusion for screw fixation from L3 to the sacrum. Additional warnings in the
package insert regarding the potential risks and unestablished benefits of the
device were also required.

In May 1990, the Director of the FDA's Division of Compliance Operations for the
Center for Devices and Radiological Health sent a letter to approximately 80
manufacturers and distributors of medical devices, including the Company, which
advised that companies must not label, or in any way promote, devices to be used
in the United States for pedicular screw attachment to, or fixation of, the
vertebral column. The Company examined all of its literature and voluntarily
recalled one brochure used to recruit clinical investigators. This recall was
examined for effectiveness by the FDA beginning in May 1991 and found to be
complete in February 1992. In August 1993, the Company and six other companies
received warning letters from the FDA, primarily regarding the issue of
supporting medical education programs where physicians "demonstrate" the use of
screws in the pedicle of the spine. The Company responded to the warning letter,
and no official response from the FDA has ever been received. In February 1995,
the Company received a warning letter from the FDA regarding the wording in a
Company press release and "Dear Doctor" letter relating to the January 1995
510(k) Clearance referred to above. The Company submitted a written response to
the FDA on March 17, 1995 and took certain actions in response to the letter.
The Company believes that it has taken all the appropriate actions possible
regarding this matter.

With respect to a different but related matter, in April and June 1994, many
orthopedic companies received letters from the FDA stating that certain warning
statements must appear on all labeling of certain devices. The Company believes
it is complying with all labeling requirements for those devices in the United
States that need such warning statements.

The Company cannot, however, rule out the possibility that the FDA could bring a
regulatory action without further notice against the Company with respect to any
of the matters referred to above. Such regulatory action might include, but
would not be limited to, civil and/or criminal penalties, an injunction against
any distribution in the United States, seizure, fines and/or recall of any
Company product or labeling. The inability to continue to sell certain products
could have a material adverse impact on the Company's business and financial
condition.

The Company's products are also subject to regulation by foreign governmental
and regulatory authorities. The Company believes that it has all necessary
foreign authorizations where its products are sold. There can be no assurances
that foreign regulatory requirements will not become more stringent in the
future. In Europe, individual European Union ("EU") members

30
32

have required compliance and testing for some devices (e.g., electromedical
devices), but in most countries testing of implants has been voluntary.

A Medical Devices Directive (the "Directive") for the EU was adopted on June 14,
1993. Proof of compliance with the harmonized standards will be presumptive
proof of compliance with the legal requirements in each EU member country. If
compliance with the standards cannot be demonstrated or standards have not been
issued for the product in question, the manufacturer will have to supply an
application that proves the product is safe and effective. While there is
uncertainty as to the specific national enabling legislation, the Company does
not anticipate any special concerns uniquely applicable to the Company since
this legislation affects all medical device manufacturers and distributors.
There can be no assurance that new legislation will not cause delays or
disruptions in the marketing of the Company's products in Europe. In 1995, the
Company's Memphis, Warsaw and French facilities were ISO 9001 certified pursuant
to the Directive. The Company believes it is well positioned to compete in the
European market when the regulations take full effect in 1998.

All of the Company's products are prescription devices for sale in the United
States only by or on the order of a physician. Neither this document nor any
other communication to the financial community by the Company is intended or
should be construed as labeling for the Company's products. Any learned
intermediary or health care professional who reads this document or any other
communication to the financial community should not rely on this document for
decisions to purchase, indications in use and/or instructions in use. Instead,
any health care professionals who may read this or any other Company document
should see, read and follow all package inserts accompanying the Company's
products.

EMPLOYEES

The Company had approximately 1,000 employees at December 31, 1997. No U.S.
employee of the Company is represented by a labor union or is subject to a
collective bargaining agreement. All of the employees outside the United States
are covered by applicable industry collective bargaining agreements as may be
required by government authorities in the respective countries where those
employees are located. The Company has never experienced a work stoppage due to
labor difficulties.

PATENTS, TRADEMARKS AND COPYRIGHTS

As of December 31, 1997, the Company owned or held licenses to 208 inventions
covered by 348 patents and had 422 applications pending on 141 more inventions
covering the full spectrum of its product lines in the United States and major
countries throughout the world. In addition, the Company has acquired rights
under various purchase, license or distribution agreements related to the
design, manufacture and distribution of certain products and devices. The
Company has 38 registered trademarks and applications pending for registration
on 36 other marks in the United States and other major countries throughout the
world. The Company currently has six registered copyrights for certain of its
product manuals and two other applications pending. See "--Principal Products"
and "Risk Factors--Dependence on Patents and Proprietary Technology."

ROYALTY AND OTHER PAYMENTS

The Company has agreements with certain unaffiliated entities which provide the
Company with the rights to manufacture and market certain spinal system products
developed by these entities. These agreements generally provide for payments
ranging from 1% to 10% of the net selling prices (as defined by the agreements)
of all such products sold. These agreements are in force as long as the Company
sells these products. Royalty expenses and licensing fees made pursuant to the
agreements referred to above during fiscal years 1997, 1996 and 1995 were
approximately $9.1 million, $6.8 million and $5.9 million, respectively.

PROPERTIES

The Company's headquarters and primary U.S. distribution facility are located in
Memphis, Tennessee. The Company utilizes a 60,000 square foot owned facility and
9,730 square feet of leased space for these functions. The Company is in need of
additional office and distribution space at its Memphis location and is planning
to lease a 106,000 square foot building that is currently under construction
adjacent to its corporate headquarters. The primary U.S. manufacturing
operations of the Company are conducted in an 83,000 square foot plant located
new Warsaw, Indiana, under a lease which expires December 31, 1999, with four
one-year extensions available thereafter. Approximately 33,000 square feet of
the Warsaw facility are currently not used by the Company. Management believes
that the Company's Warsaw facility is suitable for its current use and adequate
for the Company's operation for the foreseeable future. The Rang-du-Fliers,
France location utilizes a 57,500 square foot facility situated on 10.8 acres of
land owned by Sofamor, which also has approximately 16,000 square feet of leased
office space in Paris used for marketing, sales, development and administrative
activities. Subsidiaries of the Company have leased office

31
33

space in Milan, Italy, Cologne, Germany, Epping, NSW, Australia, Seoul, Korea,
San Juan, Puerto Rico, Mississauga, Canada, Saint Genis Laval, France, Hong
Kong, Madrid, Spain, Tokyo and Osaka, Japan, Luxembourg City, Luxembourg,
Broomfield, Colorado and West Palm Beach, Florida.

LEGAL PROCEEDINGS

The Company is involved from time to time in litigation on various matters which
are routine to the conduct of this business, including product liability and
intellectual property cases.

Product Liability Litigation

Beginning in 1994, the Company and other spinal implant manufacturers were named
as defendants in a number of product liability lawsuits brought in various
federal and state courts around the country. These lawsuits allege that
plaintiffs were injured by spinal implants manufactured by the Company and
others. The essence of the plaintiff's claims appears to be that the Company
(including Sofamor and its former U.S. distributor) marketed some of its spinal
systems for pedicle fixation in contravention of FDA rules and regulations
(governing marketing and labeling of medical devices), that pedicle fixation has
not been proven safe and effective in the context of FDA labeling standards,
that some or all of the spinal systems are defectively designed and manufactured
and that plaintiffs have suffered a variety of injuries as a result of their
physicians' use of such systems in pedicle fixation. The Company has also been
named as a defendant in a number of lawsuits instituted by plaintiffs who have
received spinal implants manufactured by other manufacturers and in which the
Company is alleged to have participated in a conspiracy among doctors,
manufacturers, hospitals, teaching institutions, professional societies and
others to promote, in violation of applicable law, the use of spinal implants.

In a number of cases, plaintiffs have sought to proceed as representatives of
classes of spinal implant recipients. All efforts to obtain class certification
have been denied or withdrawn, except with respect to a class-action settlement
entered into between the plaintiffs and another spinal implant manufacturer,
AcroMed Corporation (see below under the heading entitled "AcroMed Corporation
Settlement"). Some plaintiffs have filed individual lawsuits, whereas other
lawsuits list multiple plaintiffs and, in certain instances, multiple lawsuits
have been filed on behalf of the same individual plaintiffs. Plaintiffs
typically seek relief in the form of monetary damages, often in unspecified
amounts. Many of the plaintiffs only allege as monetary damages an amount in
excess of the jurisdictional minimum for the court in which the case has been
filed. A few suits also name as defendants various officers and directors of the
Company.

The Company believes that is has defenses, including, without limitation,
defenses based upon the failure of a cause of action to exist where no
malfunction of the implant has occurred or the plaintiff has suffered no injury
attributable to the Company's product, the expiration of the applicable statute
of limitations and the learned intermediary defense. The Company has asserted
and will continue to assert these defenses primarily through the filing of
dispositive motions. The Company believes that all product liability lawsuits
currently pending against it are without merit and will continue to defend
against them vigorously.

Federal Multidistrict Litigation (MDL 1014)

On August 4, 1994, the Federal Judicial Panel for Multidistrict Litigation
ordered all federal court lawsuits to be transferred to and consolidated for
pretrial proceedings, including the determination of class certification, in the
United States District Court for the Eastern District of Pennsylvania in
Philadelphia (the "Multidistrict Litigation"). Lawsuits filed in federal court
after August 4, 1994 have also been transferred to and consolidated in the
Multidistrict Litigation in the Eastern District of Pennsylvania. In addition, a
number of lawsuits filed in state courts around the country were removed to
federal courts and then transferred into the Multidistrict Litigation. On
February 22, 1995, Chief Judge Emeritus, Louis C. Bechtle, denied class
certification. A large number of plaintiffs filed individual lawsuits as a
result of the denial of class certification. In some instances, lawsuits that
had been removed and transferred into the Multidistrict Litigation have been
remanded to the state courts in which they were filed because there was no
federal court jurisdiction. As of December 31, 1997, the Company is a defendant
in approximately 920 individual claims and 1,065 conspiracy claims consolidated
in the Multidistrict Litigation. On April 16, 1997, Judge Bechtle dismissed
conspiracy claims alleging fraud on the FDA, but deferred the remaining
conspiracy claims for later consideration by the federal trial courts to whom
the cases will be remanded for trial.

Discovery has been completed in a number of the federal court cases and is
continuing in the remainder. A small number of cases have been transferred to
the federal courts in which they were filed for further proceedings and trial.
Judge Bechtle has

32
34

begun the process of transferring the remaining federal court cases to various
federal courts throughout the United States. As of December 31, 1997, the
Federal Judicial Panel on Multidistrict Litigation ordered the remand of
approximately 210 cases to transferor courts for further proceedings. It is not
now possible to determine when the first federal court cases will be tried.

State Court Litigation

A number of cases filed in state courts were not eligible for removal and
transfer into the Multidistrict Litigation. As of December 31, 1997, there were
approximately 1,800 individual claims pending against the Company in several
courts around the country, principally in Tennessee, Oklahoma, Texas and
Pennsylvania. In addition, there were approximately 1,600 conspiracy claims
pending in state courts.

Approximately 1,550 plaintiffs who had joined together in several complaints
which had been removed to the Multidistrict Litigation proceedings have had
their cases remanded to the state court in Memphis, Tennessee, where they were
originally filed when it was determined that the federal court lacked
jurisdiction over their claims. The presiding state court judge in Memphis has
established a case management plan which calls for the preparation of eight
representative cases for pretrial preparation and trial.

Discovery is proceeding in all remaining state court cases. Some state cases
have been given trial dates in 1998. It is anticipated that a number of other
state court cases around the country may be scheduled for trial in 1998,
although delays in trial dates are common. Trials in the Memphis proceedings are
scheduled to begin in 1998.

AcroMed Corporation Settlement

In December 1996, AcroMed Corporation ("AcroMed"), a spinal implant manufacturer
and a defendant in many of the cases pending in the Multidistrict Litigation,
and the Plaintiff's Legal Committee in the Multidistrict Litigation announced
that they had entered into a conditional settlement regarding all product
liability claims involving the use of AcroMed devices to achieve pedicular
fixation with screws in spinal fusion surgery. Under the terms of the
settlement, AcroMed will establish a settlement fund consisting of $100 million
in cash plus the proceeds of its product liability insurance policies. In
January 1997, the parties submitted a formal class settlement agreement and
related documentation for approval by Judge Bechtle. By order dated October 17,
1997, Judge Bechtle certified the proposed settlement class and approved the
proposed settlement. All federal court proceedings involving AcroMed devices
have been stayed pending final judicial consideration of the proposed
settlement.

Insurance

Several insurance carriers have asserted reservation of rights concerning the
scope and timing of the Company's remaining insurance coverage, but have not
denied insurance coverage to the Company. Three of the carriers, Royal Surplus
Lines Insurance Company ("Royal"), Steadfast Insurance Company ("Steadfast") and
Agricultural Excess and Surplus Insurance Company ("Agricultural"), have each
filed declaratory judgment actions against the Company seeking clarification of
their rights and obligations, if any, under their respective policies. Neither
Royal nor Agricultural has paid amounts due to the Company; Steadfast has paid
only a portion of the amounts due to the Company. The Royal and Steadfast
lawsuits are pending in the United States District Court for the Western
District of Tennessee in Memphis. The Agricultural lawsuit is pending in the
United States District Court for the Southern District of Ohio in Cincinnati.
The Company believes that the receivables are recoverable under the terms of the
Royal, Steadfast and Agricultural policies. The Company has filed an answer and
counterclaim in the Royal litigation and a motion seeking the interim payment of
the Company's defense costs. The Company has filed an answer and counterclaim in
the Steadfast litigation and intends to file an answer and counterclaim in the
Agricultural litigation. These litigations are in the preliminary stages. The
Company believes that Royal's, Steadfast's and Agricultural's claims are without
merit and will defend against them vigorously.

As is common in the insurance industry, the Company's insurance policies
covering product liability claims must be renewed annually. Although the Company
has been able to obtain insurance relating to product liability claims at a cost
and on other terms and conditions that are acceptable to the Company, there can
be no assurance that in the future it will be able to do so.

In January 6, 1997, the Company announced that its 1996 financial results would
include a pre-tax charge of $50 million relating to costs associated with the
product liability litigation described above. The charge, which has now been
reflected in the Company's 1996 financial statements, covers the reasonably
foreseeable costs that the Company was positioned in late December 1996 to
estimate because the litigation had progressed and because changes in the fourth
quarter of 1996 had occurred in facts and circumstances relating to the
litigation. Among the changed facts and circumstances were the announcement of
the AcroMed settlement described above, the likelihood that the litigation will
continue for several years, in

33
35

part, due to the additional financial resources provided to the plaintiffs'
attorneys as a result of the AcroMed settlement, the absence of AcroMed as a
member of the joint defense group, the status of the Company's insurance
described above and the continuing absence of dispositive rulings relating to
the Company's defense motions.

While it is not possible to accurately predict the outcome of litigation, the
amount of the accrual which remained on the Company's consolidated balance sheet
at December 31, 1997 represents the Company's best judgment of the probable
reasonable costs (in excess of amounts of insurance the Company believes are
recoverable) to defend and conclude the lawsuits based on the facts and
circumstances currently existing. The costs provided for in the accrual include,
but are not limited to, legal fees paid or anticipated to be paid and other
costs related to the Company's defense and conclusion of these matters.

Securities Laws Actions

Beginning in April 1994, the Company and four of its officers and directors were
named in five shareholder lawsuits filed in the United States District Court in
Memphis, Tennessee. Four of the lawsuits purport to be class actions. All of the
lawsuits were consolidated into one case in the United States District Court in
Memphis through an amended complaint which added four new individual defendants
who are either current or former directors of the Company. The lawsuit alleges
that the defendants made false and misleading statements and failed to disclose
material facts to the investing public and seeks money damages. The alleged
securities law violations are based on the claim that the defendants failed to
disclose that the Company sold its products illicitly, illegitimately and
improperly and to timely disclose facts concerning the termination of the former
U.S. distributor of Sofamor products, NMS. The allegations relating to illicit
and illegitimate sales of product are, for the most part, copies from product
liability complaints filed against the Company and other manufacturers currently
being coordinated in the United States District Court for the Eastern District
of Pennsylvania which are referred to above. The allegations of improper sales
relate to one of the Company's selling programs which has been publicly
disclosed since May 1991. The allegations concerning NMS relate to the
termination of the NMS distribution agreement covering Sofamor products in the
United States. On October 3, 1995, the United States District Court Judge in
Memphis dismissed with prejudice the entire case against the Company and each of
the individual defendants. The plaintiffs appealed the dismissal to the United
States Court of Appeals for the Sixth Circuit. On August 14, 1997, the Court of
Appeals affirmed the dismissal of the plaintiffs' complaint. The Court of
Appeals denied the plaintiffs' request for reconsideration on October 9, 1997.
On January 6, 1998, the plaintiffs filed a petition for certiorari in the United
States Supreme Court.

The Company does not believe the Securities Laws Actions will have a material
adverse effect on its consolidated financial position, results of operations or
cash flows because of, among other reasons, the facts and circumstances existing
with respect to each action, the Company's belief that these actions are without
merit, certain defenses available to the Company and the availability of
insurance in the Securities Laws Actions.

See "Risk Factors--Risk of Product Liability; Adequate Insurance Coverage" and
"--Dependence on Patents and Proprietary Technology."

34
36

MANAGEMENT

The name, age and position held with the Company of each of the executive
officers and directors of the Company are set forth below.

- ----------------------------------------------------------------------------------------------------------
NAME AGE POSITION
- ----------------------------------- --- -------------------------------------------------------------

E. R. (Ron) Pickard................ 49 Chairman, Chief Executive Officer and Director
James J. Gallogly.................. 49 President, Chief Operating Officer and Director
Robert A. Compton.................. 41 Group President, Operations and Director
R. L. (Lew) Bennett................ 71 Senior Vice President
Richard E. Duerr, Jr. ............. 51 Vice President, General Counsel and Secretary
Laurence Y. Fairey................. 47 President, International Division
George G. Griffin III.............. 50 Executive Vice President and Chief Financial Officer
Kenneth G. Hayes................... 45 President, Surgical Navigation Technologies Division
Mark D. LoGuidice.................. 42 Executive Vice President, New Products and Markets
Richard Mazza...................... 51 Executive Vice President, Global Manufacturing and
Distribution
J. Mark Merrill.................... 38 Vice President, Treasurer and Assistant Secretary
John Pafford....................... 38 Executive Vice President, Global Research and Development
Marie-Helene Plais, M.D. .......... 48 Executive Vice President and Director
Gene B. Sponseller................. 41 President of Manufacturing, Sofamor Danek USA
Edward Traurig..................... 40 Executive Vice President, Sales
Richard W. Treharne, Ph.D.......... 48 Vice President of Research and Regulatory Affairs
Don W. Urbanowicz.................. 42 Executive Vice President of Marketing, Sofamor Danek USA
L. D. Beard........................ 65 Director
George W. Bryan, Sr. .............. 53 Director
Yves Paul Cotrel, M.D. ............ 72 Director
Samuel F. Hulbert, Ph.D. .......... 61 Director
George F. Rapp, M.D. .............. 66 Director

In May 1998, Mr. Compton will become the President and Chief Operating Officer
of the Company. Mr. Gallogly, the current President and Chief Operating Officer
of the Company, will relinquish these positions at such time but will remain on
the Board of Directors of the Company. In addition, Mr. Gallogly will become an
exclusive consultant to the Company.

The executive officers of the Company serve at the discretion of the Board of
Directors and are appointed annually. Members of the Board of Directors serve
for one-year terms. Dr. Plais is Dr. Cotrell's daughter. No other family
relationship exists among any of the executive officers and directors. The
following is a brief description of the previous business background of each of
the executive officers and directors.

E. R. (RON) PICKARD has been Chairman and Chief Executive Officer of the Company
since May 1994. He was President and Chief Operating Officer of the Company from
August 1990 until becoming President and Chief Executive Officer in April 1991.
He was appointed as Director of the Company in February 1991. From 1968 until
joining the Company, Mr. Pickard was employed by Richards Medical Company in
varying capacities including Director of Manufacturing (1975-78), Group Director
of Manufacturing (1979-1981), Vice President, Manufacturing (1982-1985) and
President, Orthopaedics Division (1986-90). He was appointed as Director of the
Company in February 1991.

JAMES J. GALLOGLY has been President and Chief Operating Officer of the Company
since June 1994. From 1988 to 1994, he was President and Chief Executive Officer
of ReSound Corporation. He was appointed as a Director of the Company in 1994.
From 1981 to 1988, Mr. Gallogly held senior executive positions at Richards
Medical Company, including President of the Microsurgery Division (1986-1988),
Senior Vice President of Microsurgery (1982-1985) and Vice President of Finance
and Administration (1981-1982). Prior to 1981, he was employed by Johnson &
Johnson, where he held a variety of executive positions.

ROBERT A. COMPTON joined the Company in May 1997 as Group President, Operations.
He has served on the Company's Board of Directors since 1990. For 12 years prior
to joining the Company, Mr. Compton developed a successful career in the venture
capital industry, and most recently worked for the Corporation for Innovation
and Development. He first invested in the Company in 1989 and subsequently
served on the Company's Board of Directors. His past venture capital activities
have included investing in and building rapidly growing companies in the fields
of medical devices, healthcare services, information technology and
biotechnology. He received his B.A. from Principia College in 1978 and his
M.B.A. from Harvard University in 1984.

35
37

R. L. (LEW) BENNETT has been Senior Vice President of the Company since January
1992. Mr. Bennett joined the Company in January 1991 as Senior Vice
President--Sales and Marketing. He has been active in the medical industry for
over 35 years, including tenures as divisional sales manager for Ethicon and
Vice President--Sales and Vice President--Marketing for the United States,
Canada and the Far East for Howmedica, Inc. Ethicon is a division of Johnson &
Johnson that specializes in medical sutures. Howmedica, Inc. is an orthopedic
company.

RICHARD E. DUERR, JR. has been Vice President, General Counsel and Secretary
since he joined the Company in June 1991. Mr. Duerr was engaged in the private
practice of law prior to joining the Company. From October 1979 through May
1990, Mr. Duerr was employed by Schering-Plough Corporation in a variety of
domestic and international capacities. He previously served as an Assistant
United States Attorney for the Eastern District of Kentucky and as a law clerk
to the Honorable Pierce Lively, Judge of the United States Court of Appeals for
the Sixth Circuit. He received his B.A. in 1969 from the University of Notre
Dame and is a 1972 graduate of the University of Louisville School of Law.

LAURENCE Y. FAIREY has been President of the Company's International Division
since January 1998. He joined Sofamor Danek USA in January 1991 as Vice
President--International. He was appointed a Vice President and the Chief
Financial Officer of the Company in October 1991 and promoted to Executive Vice
President and Chief Financial Officer in July 1992. In July 1997, Mr. Fairey was
named President of the Company's Americas, Asia, Pacific Division. Prior to
joining Sofamor Danek USA, Mr. Fairey was employed by Richards Medical Company
since 1973 in various positions, including Controller, Treasurer, Vice President
Finance for the International Division and his last position of Vice President
of International Operations. Mr. Fairey holds a B.S. degree in accounting and an
M.B.A. from the University of Memphis.

GEORGE G. GRIFFIN III joined the Company in July 1997 as Executive Vice
President and Chief Financial Officer. For four years prior to joining the
Company, Mr. Griffin served as Chief Financial Officer and Executive Vice
President of Wright Medical Technology, Inc., and from 1988 through 1993, he
served as Vice President--Finance of Smith and Nephew Richards. Mr. Griffin has
over 18 years of management experience in the orthopedic industry. He received a
degree in accounting from Mississippi State University in 1970 and became a
certified public accountant in 1980.

KENNETH G. HAYES joined the Company in July 1997 as President, Image Guided
Surgery Division. Mr. Hayes has more than 20 years experience in the medical
devices industry and, prior to joining the Company, served as President of the
USCI Division of C.R. Bard. He received his B.S. from Marist College in 1974.

MARK D. LOGUIDICE has been Executive Vice President, New Products and Markets
since January 1998. He joined Sofamor Danek USA as President in February 1995.
Prior to that, he spent 16 years with United States Surgical Corporation, most
recently in the positions of Vice President of Marketing--Sutures and Vice
President of Sales. Mr. LoGuidice is a 1978 graduate of Colgate University and
received his M.B.A. from Pace University in 1984.

RICHARD MAZZA joined the Company in February 1998 as Executive Vice President,
Global Manufacturing and Distribution. For the four years prior to joining the
Company, Mr. Mazza was employed by Wright Medical Technology, Inc., most
recently serving as Chief Operating Officer. From 1991 to 1994, he served as
Senior Director of Operations for United States Surgical Corporation. Mr. Mazza
is a graduate of Central Connecticut State University.

J. MARK MERRILL is Vice President, Treasurer and Assistant Secretary. He joined
the Company in October 1988. Mr. Merrill received his B.S. degree in accounting
from Christian Brothers University in 1981. He became a Certified Public
Accountant in 1983 and received his M.B.A. with a concentration in finance from
the University of Memphis in 1988.

JOHN PAFFORD has been Executive Vice President, Global Research and Development
since October 1997. He joined the Company in January 1991 as Director of Product
Development. In September 1991, he was promoted to Vice President of Product
Development overseeing all U.S. product developing activities. Prior to joining
the Company, Mr. Pafford was employed by Dow Corning Wright, holding various
positions in Product Development from 1977 onward. Mr. Pafford holds a B.S.
degree in engineering from the University of Memphis and is a member of the
University's Advisory Council of the Herff College of Engineering.

MARIE-HELENE PLAIS, M.D. has been Executive Vice President of the Company since
November 1996. In August 1987, she joined the Company as Medical Director of
Sofamor, became Vice President of Marketing and Sales of Sofamor in 1989 and
President of Sofamor Danek Europe in 1993. Prior to joining the Company, she was
a consultant in genetic diseases in Brittany, France. Dr. Plais graduated from
the University of Paris as an M.D. and holds a Master's Degree in human biology.

GENE B. SPONSELLER has been President of Manufacturing, Sofamor Danek USA since
September 1990. From 1984 to 1990, he was Vice President and General Manager of
Manufacturing Operations.

36
38

EDWARD TRAURIG has been Executive Vice President, Sales since October 1997. He
joined the Company in February 1995 as Vice President, Sales. Mr. Traurig had
previously been employed with United States Surgical Corporation for 13 years
holding various positions. He holds a B.S. degree from Miami University in Ohio.

RICHARD W. TREHARNE, PH.D. has been Vice President of Regulatory and Clinical
Affairs of the Company since January 1991. He joined the Company in November
1990. Prior to that, Dr. Treharne was with Richards Medical Company. Dr.
Treharne has a Ph.D. from the University of Pennsylvania and an M.B.A. from the
University of Memphis. In June 1991, Dr. Treharne was named Vice President of
Research and Regulatory Affairs and is presently in charge of the research and
regulatory efforts of the Company.

DON W. URBANOWICZ has been Executive Vice President of Marketing of Sofamor
Danek USA since September 1995. From January 1987 until joining Sofamor Danek
USA, Mr. Urbanowicz held senior executive positions with Smith and Nephew
Richards, including President of the Perry Surgical Glove Division (1992-1995)
and Senior Vice President for Strategic Planning/Business Operations and Vice
President of Global Marketing for the Richards Orthopaedic Division. From 1980
to 1986, he was employed by Pfizer's Howmedica Orthopaedic Division, where he
held a variety of marketing management positions. Mr. Urbanowicz is a 1977
graduate of Seton Hall University. He received his M.B.A. from Seton Hall in
1980.

L. D. BEARD has been a Director of the Company since 1983. He was President and
Chief Executive Officer of the Company from 1983 to August 1990 and Chairman of
the Board and Chief Executive Officer of the Company from April 1, 1991 until
his retirement on May 23, 1994.

GEORGE W. BRYAN, SR. has been a Director of the Company since July 1992. Since
1983 Mr. Bryan has been Senior Vice President of Sara Lee Corporation and the
President of its Meat Division. Mr. Bryan is also a Director of Union Planters
Corporation and Union Planters National Bank.

YVES PAUL COTREL, M.D. has been a Director of the Company since June 1993. He
served as Chairman of the Sofamor Board from 1986 to 1993. Dr. Cotrel was the
Chief of the Spine Unit at the Calot Institute at Berck Plage from 1953 to 1977.
Dr. Cotrel acted as a consultant to the Luxembourg Public Health Ministry from
1977 to 1991 and has been Chairman of the Board of Directors of the French
Research Institute for Skeletal Diseases since 1989. Dr. Cotrel is the father of
Dr. Marie-Helene Plais.

SAMUEL F. HULBERT, PH.D. has been a Director of the Company since 1985. Since
1976, he has served as President of Rose-Hulman Institute of Technology. Dr.
Hulbert is also a Director of Citizens Bank of Western Indiana.

GEORGE F. RAPP, M.D. has been a Director of the Company since 1983. He is a
surgeon who has practiced since 1964 in Indianapolis, Indiana. He is a graduate
of the Indiana University School of Medicine. Dr. Rapp also serves as a Clinical
Professor of Orthopedic Surgery at the Indiana University School of Medicine.
Dr. Rapp served as a consultant to the Company from 1988 through December 31,
1991.

37
39

SELLING SHAREHOLDERS

On January 26, 1998, the Selling Shareholders entered into a stock exchange
agreement (the "Stock Exchange Agreement") pursuant to which the Selling
Shareholders sold all of the outstanding capital stock of Sofyc, a personal
holding company of the Selling Shareholders, which owns 3,337,272 shares of the
Company's Common Stock, for consideration consisting primarily of Common Stock.
Through its purchase of Sofyc, which conducts no business other than the
ownership of the Common Stock, the Company effectively repurchased beneficial
ownership of 3,337,272 shares of Common Stock held by Sofyc in exchange for an
aggregate of 2,806,080 privately placed shares of Common Stock, $1.0 million in
cash (less certain expenses relating to the repurchase) and the Company's
agreement to repay certain outstanding loans of Sofyc equal to approximately
$925,000. Accordingly, as a result of the transaction, the outstanding shares of
Common Stock were reduced by 531,192 shares. Upon consummation of the Sofyc
Exchange, Sofyc became a wholly owned subsidiary of the Company.

The following table sets forth certain information with respect to the Selling
Shareholders and reflects the consummation of the Sofyc Exchange.

----------------------------------------------------------------
OWNERSHIP PRIOR TO OWNERSHIP SUBSEQUENT
OFFERING TO OFFERING
---------------------- NUMBER OF ----------------------
PERCENT SHARES TO PERCENT
NUMBER OF TOTAL BE SOLD IN NUMBER OF TOTAL
NAME OF SHARES SHARES OFFERING OF SHARES SHARES
- -------------------------------------------------- --------- -------- ---------- --------- --------

Yves Paul Cotrel, M.D.(1)(2)(4)................... 1,451,434 5.9% 324,490 1,126,944 4.4%
Marie-Helene Plais(1)(3)(5)....................... 979,019 4.0 120,611 858,408 3.3
Annie Cotrel(1)(3)................................ 926,506 3.8 123,266 803,240 3.1
Benedicte Cotrel(1)(3)............................ 920,357 3.7 123,266 797,091 3.1
Marie Louise Cotrel(1)(2)......................... 1,436,276 5.8 324,491 1,111,785 4.3
Philippe Cotrel(1)(3)............................. 939,121 3.8 114,415 824,706 3.2
Yves-Regis Cotrel(1)(3)........................... 920,621 3.7 117,365 803,256 3.1
Elizabeth Cotrel Gauzan(1)(3)..................... 951,591 3.9 123,266 828,325 3.2
Catherine Cotrel Lechien(1)(3).................... 935,591 3.8 114,415 821,176 3.2
Marie-Christine Milliez(1)(3)..................... 931,091 3.8 114,415 816,676 3.2

- ---------------

(1) Includes 738,744 shares in usufruct.

(2) Includes 697,532 shares of Common Stock received in the Sofyc Exchange.

(3) Includes 176,377 shares of Common Stock received in the Sofyc Exchange.

(4) Includes 5,000 shares which he has the right to acquire within 60 days upon
the exercise of options.

(5) Includes 48,200 shares which she has the right to acquire within 60 days
upon the exercise of options.

The persons identified above may be deemed to beneficially own the shares under
the rules and regulations of the Commission, but the inclusion of those shares
does not constitute, and should not be construed as, an admission of beneficial
ownership.

In connection with the Sofyc Exchange, the parties executed a registration
rights agreement (the "Registration Rights Agreement") pursuant to which the
Company agreed to use its reasonable efforts to register 1,600,000 shares of the
Common Stock (the "Family Registrable Securities") received by the Selling
Shareholders in the Sofyc Exchange. The shares of the Selling Shareholders being
offered hereby are included herein pursuant to such registration rights. The
Registration Rights Agreement also provides for a demand registration right of
the Selling Shareholders if a registration statement relating to the Family
Registrable Securities is not effective on or prior to June 30, 1998 (the
"Alternative Family Demand"). In addition, the Registration Rights Agreement
grants Yves Paul Cotrel and Marie-Louise Cotrel an additional demand
registration right covering their shares of Common Stock remaining after any
offering of Family Registrable Securities. This registration right is
exercisable once during the three-year period beginning on the first anniversary
of the closing of the Offering, subject to the right of the Company to postpone
such registration up to two times for a period of 90 days each if the Company
reasonably determines that an offering at such time would have an adverse effect
on the Company under the circumstances then outstanding. The Selling
Shareholders have agreed to pay all costs in connection with any registration;
provided, however, that if securities of any other party are included in the
registration statement then they shall only pay their proportional interests of
expenses. If a registration is requested pursuant to the Alternative Family
Demand, but is not effective at a time reasonably prior to the date the Selling
Shareholders are required to pay capital gains taxes in France for the 1998 tax
year and the

38
40

failure to be effective results from a postponement of the registration
requested by the Company, the Company has agreed to assist the Selling
Shareholders in obtaining third-party financing on commercially reasonable terms
for the capital gains tax liability of the Selling Shareholders arising from the
transactions contemplated by the Stock Exchange Agreement and the Company shall
pay the borrowing costs incurred in connection with such financing. The Company
expects to incur a foreign tax liability of approximately $10.5 million in
connection with the Sofyc Exchange.

DESCRIPTION OF CAPITAL STOCK

The authorized capital stock of the Company consists of 150,000,000 shares of
Common Stock and 5,000,000 shares of Preferred Stock.

COMMON STOCK

Each share of Common Stock entitles the holder to one vote on all matters on
which holders are permitted to vote. Subject to preferences that may be
applicable if the Company's Preferred Stock (the "Preferred Stock") were
subsequently issued, the holders of Common Stock are entitled to dividends when,
as and if declared by the Company's Board of Directors out of funds legally
available therefor and, upon liquidation, to a pro rata share in any
distribution to shareholders. The Common Stock has no preemptive or conversion
rights or other subscription rights. There are no redemption or sinking fund
provisions applicable to the Common Stock. All outstanding shares of Common
Stock are fully paid and nonassessable, and the shares of Common Stock to be
issued hereby will be fully paid and nonassessable.

PREFERRED STOCK

The Company's Board of Directors has the authority to issue Preferred Stock in
one or more series and to fix the rights, voting rights, terms of redemption,
redemption prices, liquidation prices, liquidation preferences and the number of
shares constituting any series or the designation of such series, without
further vote or action by the shareholders. The issuance of Preferred Stock may
have the effect of delaying, deferring or preventing a change in control of the
Company without further action by the shareholders and may adversely affect the
voting and other rights of the holders of Common Stock. At present, the Company
has no plans to issue any Preferred Stock.

SHARES ELIGIBLE FOR FUTURE SALE

Upon consummation of the Offering, 3,219,229 shares may be deemed "restricted
securities" (as that term is defined in Rule 144 under the Securities Act)
including 1,206,080 shares issued to the Selling Shareholders pursuant to the
Sofyc Exchange. Such shares may be sold in the future only pursuant to an
effective registration statement under the Securities Act or in compliance with
Rule 144 under the Securities Act, or pursuant to another exemption therefrom.
Sales of Common Stock pursuant to this offering and sales of restricted
securities under Rule 144 or pursuant to a future registration statement may
depress the price of the Company's Common Stock.

The Company and each of its directors and executive officers and certain of its
securityholders, who, following the Offering, in the aggregate will hold
3,068,002 shares of Common Stock and options to purchase, as of February 2,
1998, 3,043,400 shares of Common Stock, will agree that they will not directly
or indirectly, without the prior written consent of J.P. Morgan Securities Inc.,
offer, sell, offer to sell, contract to sell or otherwise dispose of any shares
of Common Stock for a period of 90 days after the date of this Prospectus,
except that the Company may issue, and grant options to purchase, shares of
Common Stock under its current stock option and purchase plans. See "Selling
Shareholders."

TRANSFER AGENT AND REGISTRAR

The transfer agent and registrar for Common Stock is Trust Company Bank,
Atlanta, Georgia.

39
41

UNDERWRITING

The Underwriters named below (the "Underwriters"), for whom J.P. Morgan
Securities Inc., PaineWebber Incorporated and Smith Barney Inc. are acting as
representatives (the "Representatives"), have severally agreed, subject to the
terms and conditions set forth in the underwriting agreement among the Company,
the Selling Shareholders and the Representatives (the "Underwriting Agreement"),
to purchase from the Company and the Selling Shareholders, and the Company and
the Selling Shareholders have agreed to sell to the Underwriters, the respective
number of shares of Common Stock set forth opposite their names below:

---------
NUMBER OF
UNDERWRITERS SHARES
- ---------------------------------------------------------------------------------------------- ---------

J.P. Morgan Securities Inc. ..................................................................
PaineWebber Incorporated......................................................................
Smith Barney Inc. ............................................................................

---------
Total.................................................................................... 2,800,000
=========

The nature of the Underwriters' obligations under the Underwriting Agreement is
such that all of the Common Stock being offered, excluding shares covered by the
over-allotment option granted to the Underwriters, must be purchased if any are
purchased.

The Representatives have advised the Company and the Selling Shareholders that
the several Underwriters propose to offer the Common Stock to the public
initially at the public offering price set forth on the cover page of this
Prospectus and may offer the Common Stock to selected dealers at such price less
a concession not to exceed $ per share. The Underwriters may allow, and such
dealers may reallow, a concession to other dealers not to exceed $ per
share. After the Common Stock is initially offered, the public offering price
and other selling terms may be changed by the Representatives.

The Company has granted the Underwriters an option, exercisable within 30 days
after the date of this Prospectus, to purchase up to additional 420,000 shares
of Common Stock from the Company at the same price per share to be paid by the
Underwriters for the other shares offered hereby. If the Underwriters purchase
any such additional shares pursuant to the option, each of the Underwriters will
be committed to purchase such additional shares in approximately the same
proportion as set forth in the above table. The Underwriters may exercise the
option only to cover over-allotments, if any, made in connection with the
distribution of the Common Stock offered hereby.

The Company and the Selling Shareholders have agreed to indemnify the
Underwriters against certain liabilities, including liabilities under the
Securities Act, or to contribute to payments the Underwriters may be required to
make in respect thereof.

In connection with the Offering, the Underwriters may engage in transactions
that stabilize, maintain or otherwise affect the price of the Common Stock.
Specifically, the Underwriters may overallot the Offering, creating a syndicate
short position. In addition, the Underwriters may bid for, and purchase, shares
of Common Stock in the open market to cover syndicate shorts or to stabilize the
price of the Common Stock. Finally, the underwriting syndicate may reclaim
selling concessions allowed for distributing shares of Common Stock in the
Offering, if the syndicate repurchases previously distributed Common Stock in
syndicate covering transactions, in stabilization transactions or otherwise. Any
of these activities may stabilize or maintain the market price of the shares of
Common Stock above independent market levels. The Underwriters are not required
to engage in these activities, and may end any of these activities at any time.

The Company and each of its directors and executive officers and certain of its
securityholders, who in the aggregate will hold, following the Offering,
3,068,002 shares of Common Stock and options to purchase, as of February 2,
1998, 3,043,400 shares of Common Stock, will agree that they will not directly
or indirectly, without the prior written consent of J.P. Morgan Securities Inc.,
offer, sell, offer to sell, contract to sell or otherwise dispose of any shares
of Common Stock for a period of 90 days after the date of this Prospectus,
except that the Company may issue, and grant options to purchase, shares of
Common Stock under its current stock option and purchase plans.

40
42

LEGAL MATTERS

Certain legal matters with respect to the validity of the shares of Common Stock
offered hereby will be passed upon for the Company by Henderson, Daily, Withrow
& DeVoe. Hausmann & Associes is acting as counsel to the Sofyc Shareholders,
Shearman & Sterling is acting as counsel to the Company and Cahill Gordon &
Reindel, a partnership including a professional corporation, is acting as
counsel for the Underwriters in connection with certain legal matters relating
to the shares of Common Stock offered hereby.

EXPERTS

The consolidated balance sheets of the Company as of December 31, 1997, 1996,
1995 and 1994, and the consolidated statements of income, changes in
stockholders' equity, and cash flows for each of the four years in the period
ended December 31, 1997, incorporated by reference in this Prospectus from the
Company's Annual Report on Form 10-K and its Current Report on Form 8-K, dated
February 3, 1998, have been incorporated herein in reliance on the report of
Coopers & Lybrand L.L.P., independent accountants, given on the authority of
that firm as experts in accounting and auditing.

41
43

[SOFAMOR DANEK GROUP LOGO]
44

PART II

INFORMATION NOT REQUIRED IN PROSPECTUS

ITEM 14. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION

The following fees and expenses shall be borne by the Company in connection
with this offering. All fees and expenses other than the SEC and NASD fees are
estimated.(1)

SEC Registration Fee.......................................................... $ 59,072
NASD Filing Fee............................................................... 20,524
NYSE Filing Fee............................................................... 35,000
Printing and Engraving........................................................ 130,000
Accounting Fees and Expenses.................................................. 30,000
Legal Fees and Expenses....................................................... 210,000
Miscellaneous................................................................. 15,404
--------
TOTAL............................................................... $500,000
========

- ---------------
(1) Each of the Selling Shareholders will pay his or her pro rata portion of the
offering expenses.

ITEM 15. INDEMNIFICATION OF DIRECTORS AND OFFICERS

Sections 23-1-37-1 through 23-1-37-15 of the Indiana Business Corporation Law
permit a corporation to indemnify directors and officers against liability
incurred in certain proceedings if the individual's conduct was in good faith
and the individual reasonably believed, in the case of conduct in the
individual's official capacity with the corporation, that such conduct was in
the best interests of the corporation and, in all other cases, believed such
conduct was at least not opposed to the best interests of the corporation. If
the proceeding is criminal, the individual must have at least had no reasonable
cause to believe that such conduct was unlawful. The statute requires a
corporation to indemnify an individual who is wholly successful on the merits or
otherwise in the defense of any proceeding against reasonable expenses incurred
by such individual, unless the Articles of Incorporation provide otherwise. The
corporation may pay for or reimburse the reasonable expenses incurred by a
director or officer who is a party to a proceeding in advance of final
disposition of the proceeding if certain conditions are satisfied. Unless
otherwise provided in the Articles of Incorporation, a director or officer who
is a party to a proceeding may apply for court ordered indemnification. The
court may order indemnification if it determines that the director is entitled
to mandatory indemnification, in which case the indemnification will include
reasonable expenses incurred to obtain the indemnification order; or if it
determines that the director is fairly and reasonably entitled to
indemnification in view of all the relevant circumstances. Except in the case of
mandatory indemnification, a corporation may indemnify a director or officer
only after it is determined that the individual meets the standard of conduct
described above. In addition, a corporation may also indemnify and advance
expenses to an officer, whether or not a director, to the extent, consistent
with public policy, that may be provided by its articles of incorporation,
bylaws, general or specific action of its Board of Directors or contract.
Section 23-1-37-14 of the Indiana Business Corporation Law empowers an Indiana
corporation to purchase and maintain insurance on behalf of any director or
officer against any liability asserted against, or incurred by, any individual
serving in such capacity at the request of the corporation or arising out of his
or her status as such, whether or not the corporation would have had the power
to indemnify against such liability under other provisions of the Indiana
Business Corporation Law.

The Amended and Restated Bylaws of the Registrant require the Registrant to
indemnify any person who is or was a director or officer of the Registrant
against any and all liabilities and reasonable expenses incurred by such person
in connection with or resulting from any threatened, pending or completed action
or proceeding, whether civil, criminal, administrative or investigative, by
reason of the fact that such person is or was a director or officer of the
Registrant, or is or was serving at the request of the Registrant as a director,
officer, employee or agent of another corporation, partnership, joint venture,
trust or other enterprise. The Registrant shall not indemnify any director or
officer to the extent that such persons' claim for indemnification arises out of
liability (i) for any breach of the director's duty of loyalty to the Registrant
or its shareholders, (ii) for acts or omissions not in good faith or which
involve intentional misconduct or knowing violation of law or (iii) for any
transaction from which the director derived an improper personal benefit.

II-1
45

The Registrant also carries liability insurance covering officers and directors.
There is a deductible amount of $100,000 for the Registrant per claim. The
policy contains certain exclusions including, but not limited to, certain claims
by stockholders.

ITEM 16. EXHIBITS

NUMBER
ASSIGNED IN
REGULATION S-K,
ITEM 601 DESCRIPTION OF EXHIBIT
- --------------- ----------------------------------------------------------------------------------------

1.1** -- Form of Underwriting Agreement
4.1 -- Form of Certificate for Common Stock incorporated herein by this reference from the
Company's Annual Report on Form 10-K (File No. 000-19168)
5.1** -- Legal opinion of Henderson, Daily, Withrow & DeVoe dated , 1998
23.1 -- Consent of Coopers & Lybrand L.L.P.
23.2** -- Consent of Henderson, Daily, Withrow & DeVoe (included in Exhibit 5.1 filed herewith)
25.1* -- Powers of Attorney (included on the signature page of this Registration Statement)

* Previously filed.

** To be filed by amendment.

ITEM 17. UNDERTAKINGS

(a) The undersigned Registrant hereby undertakes that, for purposes of
determining any liability under the Securities Act of 1933, each filing of the
Registrant's annual report pursuant to section 13(a) or section 15(d) of the
Securities Exchange Act of 1934 (and, where applicable, each filing of an
employee benefit plan's annual report pursuant to section 15(d) of the
Securities Exchange Act of 1934) that is incorporated by reference in the
Registration Statement shall be deemed to be a new Registration Statement
relating to the securities offered therein, and the offering of such securities
at that time shall be deemed to be the initial bona fide offering thereof.

(b) Insofar as indemnification for liabilities arising under the Securities Act
of 1933 may be permitted to directors, officers and controlling persons of the
Registrant pursuant to the foregoing provisions, or otherwise, the Registrant
has been advised that in the opinion of the Securities and Exchange Commission,
such indemnification is against public policy as expressed in the Act and is,
therefore, unenforceable. In the event that a claim for indemnification against
such liabilities (other than the payment by the Registrant for expenses incurred
or paid by a director, officer or controlling person of the Registrant in the
successful defense of any action, suit or proceeding) is asserted by such
director, officer or controlling person in connection with the securities being
registered, the Registrant will, unless in the opinion of its counsel the matter
has been settled by controlling precedent, submit to a court of appropriate
jurisdiction the question whether such indemnification by it is against public
policy as expressed in the Act and will be governed by the final adjudication of
such issue.

(1) For purposes of determining any liability under the Securities Act of
1933, the information omitted from the form of prospectus filed as part of
this Registration Statement in reliance upon Rule 430A and contained in the
form of prospectus filed by the Registrant pursuant to Rule 424(b)(1) or
(4) or 497(h) under the Act shall be deemed to be part of this Registration
Statement as of the time it was declared effective.

(2) For the purpose of determining any liability under the Securities Act
of 1933, each post-effective amendment that contains a form of prospectus
shall be deemed to be a new Registration Statement relating to the
securities offered therein, and the offering of such securities at that
time shall be deemed to be the initial bona fide offering thereof.

II-2
46

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the Registrant
certifies that it has reasonable grounds to believe that it meets all of the
requirements for filing on Form S-3 and has duly caused this Amendment No. 1 to
Registration Statement to be signed on its behalf by the undersigned, thereunto
duly authorized, in the City of Memphis, State of Tennessee, on February 3,
1998.

SOFAMOR DANEK GROUP, INC.

By: /s/ E. R. PICKARD
------------------------------------------
Name: E. R. Pickard

Title: Chairman and Chief Executive
Officer

Pursuant to the requirements of the Securities Act of 1933, this Amendment No. 1
to Registration Statement has been signed below by the following persons in the
capacities indicated on February 3, 1998.

SIGNATURE TITLE
- --------------------------------------------- ----------------------------------------------------------

/s/ E. R. PICKARD Chairman, Chief Executive Office and Director (Principal
- --------------------------------------------- Executive Officer)
E. R. Pickard

* President, Chief Operating Officer and Director
- ---------------------------------------------
James J. Gallogly
* Group President-Operations and Director
- ---------------------------------------------
Robert A. Compton

* Executive Vice President and Chief Financial Officer
- ---------------------------------------------
George G. Griffin III

* Vice President and Treasurer
- ---------------------------------------------
J. Mark Merrill

* Executive Vice President and Director
- ---------------------------------------------
Marie-Helene Plais, M.D.

* Director
- ---------------------------------------------
L.D. Beard

* Director
- ---------------------------------------------
George W. Bryan, Sr.

* Director
- ---------------------------------------------
Samuel F. Hulbert, Ph.D.

* Director
- ---------------------------------------------
Yves Paul Cotrel, M.D.

* Director
- ---------------------------------------------
George F. Rapp, M.D.

- ---------------

* By power of attorney.

II-3
47

EXHIBIT INDEX

NUMBER
ASSIGNED IN
REGULATION S-K,
ITEM 601 DESCRIPTION OF EXHIBIT
- --------------- -----------------------------------------------------------------------------------

1.1** -- Form of Underwriting Agreement
4.1 -- Form of Certificate for Common Stock incorporated herein by this reference from the
Company's Annual Report on Form 10-K (File No. 000-19168)
5.1** -- Legal opinion of dated , 1998
23.1 -- Consent of Coopers & Lybrand L.L.P.
23.2** -- Consent of [ ] (included in Exhibit 5.1 filed herewith)
25.1* -- Powers of Attorney (included on the signature page of this Registration Statement)

* Previously filed.

** To be filed by amendment.